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ABSTRACT
Metabolic syndrome (MetS) is a clustering of risk factors for cardiovascular disease
(CVD) and type 2 diabetes (T2D) – two major causes of morbidity and mortality
worldwide. Heart rate variability (HRV) is a non-invasive measure of cardiac
autonomic regulation that predicts mortality and morbidity. Additionally, HRV is
reduced in CVD, T2D and MetS. As such, HRV has potential to be a novel
cardiometabolic risk factor to be included in clinical risk assessment. Therefore, the
purpose of this thesis was to examine the relationships between MetS and HRV. A
systematic review of cross-sectional studies examining relationships between HRV and
MetS was completed to consolidate existing evidence and to guide future studies. This
was followed by a cross-sectional investigation of time and frequency domain and
nonlinear HRV in a population with MetS risk factors to determine which MetS risk
factors were associated with HRV parameters. A pilot study was then conducted to
study the feasibility of conducting a mobile health (mHealth) and exercise intervention
in a rural population, which was followed by a 24-week randomized clinical trial to
examine the effects of the interactive mHealth exercise intervention compared to
standard of care exercise in participants with MetS risk factors. Overall, HRV was
reduced in women with MetS compared to those without, though there were no
differences in men. Waist circumference and lipid profiles were most commonly related
to HRV parameters when studied cross-sectionally. The changes in waist circumference
and fasting plasma glucose were associated with the change in HRV parameters when
studied longitudinally. Following the intervention period, waist circumference and
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blood pressure were improved with no other changes in MetS risk factors. HRV
parameters indicative of vagal activity were reduced over the intervention period, but
there were no changes in other HRV parameters. There were no differences in changes
between the intervention and control groups. In conclusion, MetS and HRV are
associated in women but not men. However, there were no clear associations between
MetS and HRV to suggest that HRV would be a valuable clinical risk indicator.

Keywords:
Heart rate variability; autonomic nervous system; metabolic syndrome; mobile health;
physical activity prescription; cardiovascular risk.
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CHAPTER 1
Review of the Literature
1.1 Burden of Cardiovascular Disease and Type 2 Diabetes
Cardiovascular diseases (CVD) are the leading cause of death world-wide accounting for
48% of mortality from non-communicable diseases [1]. Additionally, CVDs are
responsible for a significant proportion of morbidity accounting for 10% of global disease
burden [1]. The Public Health Agency of Canada estimated the cost of CVD in Canada
as $22.2 billion in 2000, with $7.6 billion in direct health care costs and $14.6 billion in
indirect costs, including lost economic productivity [2].
Type 2 diabetes mellitus (T2D) is an independent risk factor for CVD and cardiovascular
complications are common in this patient population. Complications range from
microvascular disease including retinopathy to macrovascular disease including coronary
heart disease and stroke. In 2004, heart disease was responsible for 68% and stroke was
responsible for 16% of all deaths in patients diagnosed with T2D in the United States [3].
In 2009, annual diabetes-related spending was $113 billion in the United States, and this
is expected to increase to $336 billion in 2034 [4]. With an increasingly aging and
overweight population, the incidence and thus costs associated with CVD and T2D are
expected to increase. Strategies for cost effective management of cardiovascular risk
factors to prevent or delay disease progression and reduce disease burden are needed.
1.2 Cardiometabolic Risk
The Canadian Cardiometabolic Risk Working Group defines cardiometabolic risk as any
factor that increases the risk of cardiovascular morbidity and mortality [5]. Three
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primary categories of cardiometabolic risk are: 1) Global cardiometabolic risk, which
encompasses all novel and emerging risk factors along with the traditional factors; 2)
Metabolic syndrome (MetS), which is a specific set of risk factors that, in combination
increase the relative risk of developing CVD and T2D; and 3) Traditional risk scores,
such as the Framingham Risk Score, which use validated mathematical algorithms to
calculate an absolute cardiovascular risk [5]. The following section will discuss what
MetS is and how it can be used in combination with absolute risk scores to classify risk.
Importantly, heart rate variability (HRV) will be discussed including methodological
details, physiological background, and potential as an emerging, novel cardiometabolic
risk factor.
1.2.1 Metabolic Syndrome
Cardiovascular risk factors tend to cluster in a given individual. In 1988, Reaven
described what he termed “Syndrome X” – a combination of insulin resistance,
hyperglycaemia, hypertension, reduced high density lipoprotein cholesterol (HDL) and
increased low density lipoprotein cholesterol (LDL) [6]. The importance of considering
the increased risk of developing CVD and T2D in individuals with clustering of these risk
factors was recognized. Since that time, Syndrome X has been re-named MetS, and the
risk factors have been modified. There are a number of MetS definitions, all with slightly
different criteria. The National Cholesterol Education Program – Adult Treatment Panel
III (ATPIII) guidelines are most widely used criteria as they are more focused on allround CVD risk. Diagnosis requires the presence of three of the following five risk
factors in an individual: increased waist circumference (WC), blood pressure (BP),
fasting plasma glucose (FPG) and triglycerides (TG) and reduced HDL, all of which are
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readily measured in clinic settings [7]. MetS increases the five-year risk of developing
CVD two-fold, and the lifetime risk of developing T2D five-fold [8].
The Canadian Cardiometabolic Risk Working Group emphasizes that MetS is a relative
risk indicator and therefore, its importance will vary based on absolute cardiovascular
risk [5]. They suggest that consideration of MetS status along with an absolute risk score
may be ideal for clinical risk profiling. As a relative risk indicator, the presence of MetS
would approximately double an absolute cardiovascular risk score. For example, an
individual with a Framingham Risk Score of 2% with MetS would only have a combined
ten year risk of developing CVD of 4%, while an individual with a Framingham Risk
Score of 20% with MetS could be considered to have an actual risk of 40% [5].
Longitudinal studies are needed to determine the precise algorithm for the relative risk
calculation, but the hypothetical scenario presented by the working group demonstrates
that MetS may be particularly dangerous to individuals with high absolute risk scores.
1.2.2 Heart Rate Variability
Control of the heart is complex with input from many systems, including the nervous
system. The autonomic nervous system has two main branches: 1) The parasympathetic
nervous system, which is responsible for slowing heart rate (HR) and reducing
myocardial contractility; and 2) The sympathetic nervous system, which speeds HR and
increases myocardial contractility. Proper cardiac control is reliant on the proper
function of and balance between these two branches of the autonomic nervous system.
Heart rate variability (HRV) is a non-invasive indicator of cardiac autonomic function
with important prognostic value. Measurement involves collection of consecutive R-R
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intervals (RRI) from an electrocardiogram (ECG) or HR monitor. Commonly, either
long-term recordings of 24 hours or short-term recordings of five minutes duration are
analysed. Since overall variability is dependent upon the length of the recording, HRV
should only be compared within or between individuals if the same length of data was
analysed [9]. It is necessary to remove non-sinus rhythm beats, such as premature
ventricular contractions, before analysis. A number of different mathematical analyses
may be carried out to calculate HRV.
Time domain analysis
Time domain analysis is commonly used due to the relative ease of calculation and
because stationary data is not required. Therefore, it can be used to analyse 24 hour data.
Primary time domain indices are the standard deviation of normal-to-normal intervals
(SDNN), root mean square of successive differences (RMSSD) and the percentage of
normal-to-normal intervals greater than 50 ms (pNN50). Administration of low-dose
scopolamine to enhance parasympathetic cardiac outflow increased SDNN 23%, RMSSD
49% and pNN50 78%, suggesting significant contribution of vagal activity to each HRV
parameter, and substantial contribution to RMSSD and pNN50 [10]. SDNN is an index
of total cardiac variability over the recording period, while RMSSD and pNN50 measure
short-term variation and are reflective of parasympathetically mediated processes [9].
However, RMSSD is used preferentially over pNN50, as the mathematical algorithm is
more robust [9].
Frequency domain analysis
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Frequency domain analysis has been used extensively in research. The RRI time series is
decomposed into underlying frequencies using Fast Fourier Transform or Autoregressive
modeling. Each frequency band is classically considered to represent physiological
processes, though there is much debate around this issue. Signal stationarity is essential
for valid calculation, so short-term recordings are most applicable, though data can be
separated into equal length epochs (i.e. one hour) and averaged for the 24-hour collection
period. The power spectrum is composed of four power frequency bands: ultra low
(ULF; 0-0.003Hz), very low (VLF; 0.003-0.04Hz), low (LF; 0.04-0.15Hz) and high
frequency power (HF; 0.15-0.4Hz). Total power (TP) is often calculated as well, as are
both LF and HF in normalized units [LFnu = LF/(LF+HF); HFnu = HF/(LF+HF)] and
LF/HF.
The physiological backgrounds of the ULF and VLF bands are not as well studied as
other measures. Serrador and colleagues [11] showed that ULF was reduced during an
approximately three-hour session of inactivity (i.e. sitting and reading) compared to a day
of typical daily activity (i.e. activities of daily living, not exercise). Since ULF was
strongly correlated to the quantity of muscle activity, authors suggested that ULF may be
related to mechanisms associated with modulation of energy expenditure [11].
Generally, ULF is interpreted to be reflective of thermoregulation or hormonal systems.
Bernardi and researchers [12] showed that rhythmic or spontaneous physical activity
increased VLF power three- to five-fold compared to rest, suggesting that some aspects
of energy expenditure may be represented in VLF as well. There is also evidence to
support some contribution of the renin-angiotensin system to VLF power, but enalaprilat
administration to block angiotensin converting enzyme only modestly increased VLF
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power by 21% [13]. However, atropine administration to abolish vagal outflow reduced
VLF power 92% in healthy young adults, suggesting parasympathetic influence is the
primary physiological component of the VLF band [13].
Early studies concluded that LF was an index of sympathetic activity [14], but many
studies since have proved otherwise. Cardiac noradrenaline spillover, the gold standard
measurement of cardiac sympathetic outflow, was not correlated with LF power [15,16]
and cardiac β-adrenergic stimulation decreased LF, rather than increased as would be
expected [17]. Additionally, in conditions known to increase sympathetic outflow, such
as congestive heart failure [18,19] and aging [20,21], LF is decreased. In fact, age is the
major determinant of LF oscillations at rest, with reduced LF associated with advancing
age [22]. Additionally, in patients with pulmonary hypertension, LF power is negatively
associated with muscle sympathetic nerve activity [23]. Exercise is a powerful
sympathetic stimulation and LF was decreased during a bout of incremental exercise
[24]. On the other hand, LF was reduced in response to atropine, a cholinergic blockade,
suggesting parasympathetic influence [13]. There is some evidence to support an
association between LF power of HRV and baroreflex function – one of the reflex control
mechanisms for autonomic cardiac modulation. LF power and baroreflex sensitivity
were positively correlated [16,25] and LF was increased in participants with normal
baroreflex function in response to baroreflex stimulation, but not in those with impaired
baroreflex sensitivity [26]. These findings provide a basis for future investigations, but
are not conclusive. To date, the physiological meaning of the LF power band of HRV
remains controversial.
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Resting HF is classically considered to be mediated by respiratory sinus arrhythmia when
breathing is greater than 0.15Hz, or about nine breaths per minute [9]. HF is often
thought to quantify vagal tone since HF power of HRV is nearly completely abolished by
parasympathetic blockade with atropine [27,28] or glycopyrolate [29,30]. However, an
important distinction is that HF actually reflects the modulation of vagal tone, rather than
the tonic level per se [31]. HF was reduced following both a parasympathetic blockade
with atropine and parasympathetic withdrawal with nitroprusside; despite similar levels
of absolute parasympathetic tone in both conditions, HF was lower during the
parasympathetic blockade than during parasympathetic withdrawal [31]. Similarly,
incremental doses of vagotonic atropine to increase parasympathetic tone were not
correlated to HF or other HRV indices [32]. Research supports modulation of vagal tone
as the primary underlying physiological process represented by the HF band.
Nonlinear analysis
Nonlinear analyses differ from time and frequency domain analysis as rather than
quantifying the amount of variability they examine heart rate qualities such as fractal
characteristics and complexity. Detrended fluctuation analysis quantifies the fractal-like
properties of the tachogram [33]. RRI fluctuations are calculated in windows and a loglog curve is plotted. The slope of the first arm of the curve defines the short-term scaling
exponent (α1: from 4-11 beats). When α1 is equal to one, RRI fluctuations are exhibiting
fractal-like behaviour [34,35]. Fractal breakdown can occur with either excessive order
(α1 = 1.5) or uncorrelated randomness (α1 = 0.5) [34]. Pharmacologic vagal blockade
with glycopyrolate increased α1 from a value indicative of fractal like behaviour towards
uniformity [36]. In response to physiological stimuli, α1 was increased with exercise,
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head up tilt greater than 20 degrees [37] and cold hand immersion [35], all of which
reciprocally increase sympathetic and reduce parasympathetic activity. Cold face
immersion, which co-activates sympathetic and parasympathetic outflow, resulted in
breakdown of fractal-like behaviour demonstrated by increased α1 in all subjects [35]. In
contrast to these studies, Tan and associates [38] reported no changes in α1 following
total autonomic blockade or during tilt. However, baseline values of α1 were lower in
this study than others and authors reported that participants did not demonstrate fractal
patterns at rest. This group also showed that α1 was not reproducible within individuals
[38]. Thus, the physiological background of α1 remains unclear. Considering solely
autonomic function may be too simplistic as fractal behaviour likely results from the
complex interplay of all mechanisms of cardiac control.
Poincaré Plots
Poincaré plots are often considered nonlinear since the visual appearance of the
scattergrams may be interpreted, but statistical algorithms can also be applied to quantify
plots. To construct the Poincaré plot, each RRI is plotted against the preceding RRI. The
width (SD1) and length (SD2) of the scattergram can be calculated. SD1 was reduced
with atropine and increased with scopolamine [39] and is considered a measure of shortterm variability, primarily of parasympathetic origin, while SD2 is a measure of total
variability [40,41]. Since stationarity is not required, SD1 may be used in place of HF to
quantify the vagal component during a dynamic stimulus, such as exercise.
Summary of the physiological background of heart rate variability
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In summary, modulation of the parasympathetic outflow, rather than parasympathetic
tone, appears to be the main contributor to time and frequency domain and Poincaré plot
parameters. The physiologic mechanisms related to nonlinear HR dynamics remain
debatable, as do specific mechanisms associated with the lower frequency power bands.
Since HRV represents complex physiological interactions, it is difficult to isolate specific
mechanisms. Physiological manoeuvres, such as tilt, to stimulate autonomic nervous
responses also affect hormonal and other body systems. Likewise, pharmacological
agents to stimulate or block autonomic processes may have unintended systemic or local
effects that may alter HRV.
Although there are a number of limitations associated with HRV data processing and
interpretation, it is used extensively in research and it has been suggested as a valuable
clinical tool. Since it is non-invasive and RRIs are easily collected, HRV is a useful tool
for examining autonomic function in large population studies. These characteristics give
HRV the potential to be a useful clinical tool as a novel cardiometabolic risk indicator.
The following section explores this potential in greater detail by discussing the prognostic
value of HRV.
Predictive value of heart rate variability
A landmark study showed that post-myocardial infarction patients with reduced HRV
(24h SDNN < 50 ms) had triple the risk of all-cause mortality compared to those with
higher SDNN [42]. Similarly, post-myocardial infarction patients with 24h SDNN < 70
ms had a 2-year mortality of 10% compared to 2% in patients with normal SDNN [43].
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Reduced ULF and VLF components of frequency domain analysis have been linked to
patient prognosis following myocardial infarction [44-46].
Research has also examined the prognostic value of short-term HRV in general
populations. It has been reported that over a mean follow-up of 9.2 years, those who died
had impaired autonomic function demonstrated by reduced SDNN, LF and HF, though
there were no differences in LF/HF [47]. Importantly, HRV is reduced in T2D [48,49], a
population with a high risk of CVD. Furthermore, those presenting with autonomic
impairment and T2D had approximately double the risk of mortality compared to those
with autonomic impairment, but without T2D [47]. These studies suggest an interactive
effect between traditional cardiovascular risk factors and autonomic function.
A number of studies have examined associations between MetS or its component risk
factors and HRV [50-64]. Generally, HRV is reduced in MetS compared to healthy
populations and some MetS risk factors were associated with HRV parameters.
However, these associations vary considerably based on the study population. A critical
examination and review of these findings is needed to synthesize results.
More work is needed in this area to determine specific HRV thresholds for CV risk, as to
date, they have been arbitrarily determined based on quartiles. Assuming HRV
parameters reflect different physiological processes, alteration of specific HRV
parameters may indicate risk for specific disease processes. Despite the need for more
knowledge of the physiological background of HRV parameters, evidence to date
supports the prognostic value of HRV, suggesting it may be a useful global
cardiometabolic risk factor to be considered in risk profiles.
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1.3 Risk Management
An Archimedes model of the United States population showed that 78% of adults were
candidates for CVD prevention activities, including aspirin administration, weight
reduction and control of BP, FPG and lipids [65]. If everyone took part in the prevention
activities for which they were candidates, incidence of myocardial infarction and stroke
would be reduced by 63% and 31%, respectively [65]. Even when more feasible
participation levels were considered, myocardial infarction and stroke could be reduced
36% and 20%, respectively [65]. However, with the current modes of intervention
delivery, the only cost-effective prevention activity was smoking cessation [65]. Thus,
strategies are needed to develop cost-effective prevention programs targeting other
important risk factors.
Insufficient physical activity is the fourth leading risk factor for cardiovascular mortality,
behind raised BP, tobacco use and raised FPG [1]. According to accelerometer data 85%
of Canadians [66] and 90% of Americans [67] are not meeting recommended physical
activity guidelines. Greater cardiorespiratory fitness has been shown to provide a strong
protective effect, attenuating the effects of MetS on all-cause and cardiovascular
mortality in men [68]. Thus strategies for delivery of cost-effective interventions for
increased physical activity, especially those aimed at increasing cardiorespiratory fitness,
have the potential to substantially reduce CVD burden. The next section discusses the
efficacy of exercise training as a cardiometabolic risk modifier by examining effects on
MetS and HRV.
1.3.1 Exercise interventions in Metabolic Syndrome
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Health behaviour modification, including increased physical activity to meet global
guidelines [69], is recommended as a primary treatment strategy for cardiometabolic risk
[5,8]. The effects of exercise on individual MetS risk factors have been reviewed
extensively [5,70,71]. However, only one meta-analysis has examined the effects of
exercise on MetS risk factors in studies on populations with MetS [72]. Of the studies
included in the meta-analysis, training interventions were eight to 52 weeks duration,
frequency of two to five sessions per week for 40-60 minutes per session at moderate to
high intensity, with the exception of one study which examined low intensity exercise.
Endurance exercise training reduced WC, SBP and DBP and increased HDL, with no
changes in FPG or TG [72]. Authors suggested that the reduction in FPG may have
reached statistical significance had baseline values been higher, but since only one study
included individuals with T2D, FPG was relatively normal prior to exercise training [72].
High intensity interval training resulted in greater improvements in FPG than moderate
intensity continuous exercise of the same volume, while changes in WC and BP were
similar between groups [73]. Since few studies included in the systematic review
included high intensity exercise, this may also explain lack of change in FPG. However,
with low levels of participation in physical activity, moderate intensities may be more
acceptable for the general population and therefore more likely to be adopted into daily
habits than vigorous activity.
The Diabetes Prevention Study and Diabetes Prevention Program were two landmark
studies investigating the effects of lifestyle intervention on disease progression. The
Diabetes Prevention Study compared a lifestyle intervention aimed at increasing physical
activity and dietary fibre and reducing saturated fats with a 5% weight loss goal to a
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control group [74]. Participants were aged 40-65y, overweight and presented with
impaired glucose tolerance [74]. After a mean study duration of 3.2y, MetS risk factors
WC, SBP, DBP, FPG and TG were reduced to a greater extent in the intervention
compared to the control group, with no differences in HDL. Additionally, after two
years, the risk of developing type 2 diabetes was 58% lower in the intervention than the
control group [74]. At four [75] and nine [76] years following cessation of the
intervention, relative risk remained 43% and 38% lower, respectively in the intervention
group. Risk reduction was predicted by adherence to the lifestyle changes after the
program had stopped [75,76], highlighting the importance of post-program support.
The Diabetes Prevention Program similarly compared an intensive lifestyle intervention,
but to pharmacological therapy with metformin or placebo plus standard lifestyle
recommendations [77]. Participants were aged 25y and up, overweight and had impaired
glucose tolerance [77]. At an average follow-up of 2.8y, incident diabetes was reduced by
31% in the metformin group and 58% in the intensive lifestyle intervention group
compared to the placebo group [77]. Following this intervention, all participants were
invited back for a long-term follow-up with the intensive lifestyle intervention and after
ten years, the incidence of diabetes was equal in all groups, now receiving equal lifestyle
advice and support [78]. This is supported by a recent meta-analysis which demonstrated
the effectiveness of both pharmacological and lifestyle interventions in reversing MetS
[79]. When MetS was treated with anti-diabetic, lipid controlling or appetite suppressant
pharmacotherapy, the odds of MetS reversal was increased 60% compared to control with
no intervention, and when MetS was treated with lifestyle intervention (dietary or
exercise advice or supervised exercise), the odds of MetS reversal was increased almost
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four-fold compared to control [79]. Although the heterogeneity of studies included in the
analysis prevented conclusive results, there was an 87% probability that lifestyle
interventions were more effective than pharmacological interventions [79]. Together,
these studies highlight the importance of lifestyle interventions, including physical
activity, to treat MetS risk factors and importantly to prevent development of disease.
1.3.2 Exercise interventions to improve HRV
Studies investigating the effect of exercise on HRV have had mixed results. An early
study showed that young adults with mild hypertension who completed 22 minutes of
calisthenics followed by 20 minutes of jogging a minimum of five times per week
increased resting RRI and HFnu and reduced LFnu [80]. A 30-week exercise training
intervention, walking or jogging three to four times per week for 30 minutes per day at
68-81% HR reserve increased SDNN in middle-aged to older men [81]. Similarly, in
post-menopausal women, lower intensity exercise at 50% of maximal oxygen uptake
(VO2max) three to four times per week for 45 minutes increased RMSSD, SDNN and
absolute values of frequency domain HRV parameters, with no change in LFnu or HFnu
[82]. One study in T2D patients with and without cardiac autonomic neuropathy showed
improvement in HRV parameters following six months of aerobic exercise three times
per week at 70-85% of HR reserve [83]. Other studies also showed improvements in
HRV in sedentary men following eight weeks of exercise training 6 days per week for
30-60 minutes per session [84,85], and these improvements were partially preserved
following 10 months of post-program home-based exercise [84]. Conversely, one study
showed no change in HRV parameters at rest or during exercise in older men and women
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after eight weeks of aerobic exercise training three times per week for 60 minutes each
session [86].
Other studies found that while resting HRV was not altered with endurance training,
HRV was altered during exposure to stressors [87-89]. One session of high-intensity
training and one session of low-to-moderate intensity exercise per week for 14 weeks
reduced HR and increased HRV at the same absolute workload following training, but
there were no differences in resting HRV, or HRV at the same relative workload [88].
Similarly, in obese women with and without T2D, 16 weeks of moderate intensity
endurance training (65%VO2max) four days per week increased post-exercise HR
recovery, HF and LF with no changes in resting HRV [87]. Six months of exercise
training two days per week for 70 minutes at moderate intensity did not affect resting
HRV in T2D patients, but HFnu was increased and LF/HF reduced during an orthostatic
challenge [89]. Reasons for discrepancies between trials may be due to exercise program
or population characteristics.
Frequency of exercise training may be an important factor, as those with sessions five to
six times per week [80,84,85] showed improved HRV, while in those with training
sessions four times per week or less, results were mixed. In four studies that did not
show changes in resting autonomic function, exercise training frequency was only two or
three times per week or only one session per week was supervised and the remaining
were completed at home, so compliance to the exercise protocol may not be as high as
reported.
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Exercise duration, on the other hand, did not affect HRV modifications toward vagal
dominance following an eight-week aerobic exercise intervention [85]. Thirty or 60minute sessions six times per week at approximately 75% VO2max had similar effects on
frequency domain HRV parameters and fractal correlation properties of RRI data [85].
Again, moderate-to-vigorous activity on most days of the week appears to be important
for HRV modification, though duration longer than 30 minutes does not seem to have
added value.
Exercise intensity may play a role in modifying HRV. Cornelissen and associates [90]
showed that healthy adults aged 55 years and older completing three one-hour exercise
sessions per week for ten weeks reduced RRI when intensity was both 33% and 66% of
HR reserve. However, only the lower intensity group increased TP, though there were no
changes in other HRV parameters in either group [90]. However, a number of exercise
interventions with moderate-to-vigorous intensity exercise reported change [80,81,8385]. Differences may be due to participant characteristics. Overtraining has been shown
to reduce HRV in athletes [91], so in the general population and especially in sedentary
and patient populations HRV may be reduced at lower training loads. Kiviniemi and
colleagues [92,93] developed a protocol whereby daily training intensity was prescribed
according to morning HRV. If HRV was increased, higher intensity exercise was
prescribed, or if HRV was reduced lower intensity exercise or a day of rest was ordered
[92,93]. This unique protocol may produce the ideal exercise training program
optimizing frequency and intensity based on individual physiological state.
Age may be important factor in HRV responses to exercise. Lee and colleagues [94]
examined the effects of low doses of atropine (which are parasympathomimetric, as
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opposed to higher doses, which are parasympatholytic) on changes in RRI and HRV in
young and old fit and unfit individuals. While resting RRI was increased in fit
individuals compared to unfit, the responses to parasympathomimetic atropine were
affected by age and fitness did not attenuate age-related declines in response [94]. Thus
the lack of change in HRV in response to exercise training may be due to reduced
function or sensitivity of the sinus node with age, which may not be modified with
intervention. One study in older women showed that exercise improved HRV when 50%,
100% or 150% of national exercise guidelines was completed; however, in women aged
> 60y, there were no improvements at lower exercise doses – only higher ones [95].
These findings suggest that improved HRV may be less attainable in older age groups
and that achievement of National physical activity guidelines may be especially
important in older populations to manage cardiometabolic risk.
In the Diabetes Prevention Program, intensive lifestyle modification (physical activity
and low fat diet) reduced HR and increased SDNN and RMSSD compared to metformin
or placebo [96]. Importantly, reductions in HR and increases in SDNN and RMSSD over
time were associated with lower risk of incident diabetes, independent of weight loss and
physical activity in the lifestyle modification group, supporting the use of HRV or the
change in HRV in response to an intervention, as a risk indicator [96]. HRV was
measured from 10s ECG segments, so neither frequency domain nor nonlinear
parameters could be examined, which also have important prognostic power, as reviewed
earlier. Nevertheless, these results are promising and suggest that lifestyle modifications
are important for risk reduction in a diabetes prevention strategy.
1.4 Strategies for exercise programming
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There is a plethora of evidence to support exercise as an important component of
cardiovascular risk reduction and diabetes prevention programs. While supervised
exercise is important in clinical studies to ensure program compliance and to properly
control factors such as exercise intensity and duration, implementation of such programs
at a population level would be costly and impractical. The following section discusses
two strategies for exercise intervention that have potential to cost-effectively reach a
large population and effectively reduce cardiometabolic risk.
1.4.1 Exercise Prescription in Primary Care
Exercise prescription in primary care has proved to successfully engage patients in
healthy physical activity behaviours [97] and receiving a written prescription is more
effective than oral advice [98]. The Step Test and Exercise Prescription (STEP™) is an
effective tool for testing fitness and providing a written exercise prescription in primary
care [99] and it has been validated in adults aged 18-85 years [100,101]. The STEP™
fitness assessment involves stepping up and down a set of two steps (each with a rise of
20cm) 20 times at a pace the participant would normally climb the stairs [99]. Since
there was no difference in outcome when the test was completed at a normal or a fast
pace, a normal pace was selected to make the test safer for a broader population [101].
Post-exercise HR is palpated from the radial artery and included in a predictive equation
for VO2max. Appendix 1 provides the full STEP™ protocol including the predictive
equation. Following the step test, an exercise prescription is written including fitness,
fitness rating, a target exercise HR and recommendations for aerobic exercise based on
national guidelines.
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Implementation of STEP™ requires few resources. In primary care it can be delivered
either by a physician or allied health professional, and counseling can be done
individually or in groups. Additionally, STEP™ is also valid when a standard staircase or
kitchen step stool is used in place of the original STEP™ unit [102]. Since few resources
are needed, STEP™ could also be implemented in community settings to reduce the
burden on family health teams and to reach individuals who do not have a family
physician.
A recent systematic review and meta-analysis showed that STEP™ was the only exercise
prescription in primary care intervention protocol that showed significant effects on
cardiorespiratory fitness [103], which is important considering that increased
cardiorespiratory fitness reduced cardiovascular mortality [68]. Authors hypothesized
that this was due to one feature that was unique to STEP™, which was the inclusion of
prescription of a target exercise HR [103]. Global guidelines recommend accumulating
150 minutes of moderate-to-vigorous aerobic activity weekly for optimal health benefits
[69]; thus, inclusion of target exercise HR could be an important component to the
exercise prescription to ensure that the appropriate exercise intensity is reached.
STEP™ has proved to be an effective tool, particularly as a first-line treatment for MetS.
A recent review showed that STEP™ effectively improved MetS risk factors by reducing
WC, BP and FPG, although there were no changes in TG or HDL despite positive
changes in total and LDL cholesterols [99]. STEP™ intervention has also improved
more novel cardiometabolic risk factors, including carotid artery β-stiffness index,
distensibility and strain [99]. Thus, STEP has the potential to be an important tool, either
in the clinic or community, for cardiometabolic risk management. Since STEP
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interventions have consistently improved cardiorespiratory fitness and cardiometabolic
risk factors, HRV may also be positively influenced, though this has not yet been
examined.
1.4.2 Mobile Health Interventions
Electronic health (eHealth) is defined as “an emerging field in the intersection of medical
informatics, public health and business, referring to health services and information
delivered or enhanced through the Internet and related technologies” [104]. mHealth is a
branch of eHealth with essentially the same goals, but with the added benefit of mobility
and portability, since the technological medium is a mobile phone. In the United States,
85% of the population owns a mobile phone, and in this group smartphone ownership has
risen from 33% in May 2011 to 53% in November 2012 [105]. With the rapid growth of
smartphone users, mHealth interventions allow for the potential to reach a broad
population. Importantly, many lower income and minority groups have opted to own a
smartphone instead of a home computer as a more cost-effective means to combine
mobile phone and internet service [106]. In fact, world-wide, the use of short message
service (SMS – text messaging) is approximately double that of the internet [107].
There are a number of potential benefits to mHealth interventions. Firstly, as already
mentioned, they have the potential for broad reach, since a large proportion of the
population owns a mobile phone [105]. Secondly, much like other eHealth interventions,
they allow for interactivity to engage users. Interactivity is important for communication
between users or between users and technology and it is sometimes considered necessary
for behaviour change [108]. Thirdly, since many keep their mobile phone nearby at all
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times, it has the potential to act as a trigger or call to action to complete a behaviour. The
iStepLog smartphone application was developed to supplement the 10,000 Steps internetbased program and researchers showed that participants used the smartphone application
71.2% of the time and the website only 28.8% of the time [109]. With the opportunity to
use either medium for intervention support, smartphone was more popular, possibly
because of the increased convenience. Fourth, with internet connectivity, smartphones
can empower users by allowing the ability to search for health information when it is
needed.
While mHealth interventions have the potential to reach a broad population, there are
some limitations. First, since technology changes so quickly, it is difficult to run and
complete robust clinical trials before new and improved applications and technologies are
available and privacy must be ensured according to HIPPA or other governing bodies.
Secondly, there are subgroups of the population with less access to mobile phones, and
some of these are important groups for health interventions, such as the elderly [106].
Lastly, additional costs to activate some features of mobile phones may prevent or limit
the ability of some to use mHealth interventions to their fullest potential [106].
A recent meta-analysis of mHealth interventions to increase physical activity reported
increased pedometer steps, but no change in moderate-to-vigorous physical activity
duration [110]. This may be due to differences in populations, as the three studies
included in the analysis that examined pedometer steps included adults and one of these
was for chronic obstructive pulmonary disease rehabilitation, which may have increased
motivation to comply to the intervention. In contrast the studies examining changes in
moderate-to-vigorous physical activity duration included one group of children, one of
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teenagers, and the remaining three were of adults, including one group of post-natal
women. Older adults are more compliant with technology interventions [111], which
may account for differences. The results of the meta-analysis should be interpreted with
caution. Authors noted that due to the few numbers of published studies, those included
in the analysis were rather heterogeneous [110]. Study duration ranged from two to 52
weeks, age ranged from children to older adults, and intervention delivery varied greatly,
despite the fact that mobile phones were used in all studies. Additionally, most studies
using mobile platforms did not use the full range of features and many used only SMS for
reporting and follow-up.
Research to date supports the use of mHealth interventions for diabetes management. In
a meta-analysis of 22 studies, Liang and associates [112] reported that reductions in
glycated hemoglobin (HbA1c) were 0.5% greater in the mHealth groups compared to
control groups, and this difference was even greater in T2D (0.8%). Trials included in
this meta-analysis were three to 12 months duration and the interventions using the
mobile phone were diverse. Most interventions included transmission of self-monitored
FPG, though some used the mobile phone for education only. Twelve of the trials used
mobile phone in conjunction with internet as the medium for intervention delivery. Two
trials compared internet-based to mobile phone-based interventions. One showed that
improvements in HbA1c levels, satisfaction levels and adherence to study protocols were
similar between groups [113], while the other showed no change in HbA1c in either
group, but there were differences in intervention use [114]. The mobile phone-based
group responded to more reminders to check glucose, but the internet-based group
submitted more measurements without reminders. Submission of measurements was
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higher in the mobile phone group at the beginning of the intervention and decreased in
both groups such that in the final month of a three-month intervention, only one of
eighteen receiving email reminders and three of twenty-two receiving SMS reminders
continued to submit measurements [114]. Together these findings suggest that while the
overall results of mHealth versus internet-based interventions may be similar, use of
these technologies is different. Interventions may have greater impact if device use is
investigated and future protocols are developed according to use patterns.
Evidence also supports the use of mHealth technology for BP control in patients with
T2D and uncontrolled hypertension. Logan and colleagues [115] tested the effects of a
one-year self-care support intervention, in which participants received a smartphone and
Bluetooth enabled BP monitor. Once participants submitted BP measurements, they
received automated feedback via smartphone application. If BP was outside of predetermined limits, they were prompted to take additional measurements and to schedule
physician follow-up appointments if needed. Compared to a control group, who
monitored BP, but did not get feedback, the intervention group reduced daytime
ambulatory systolic BP by 9 mmHg, while there was no change in the control group
[115]. Importantly, all of the self-care messages were automated and neither researchers,
nor health care workers were regularly in contact with participants throughout the trial.
Interventions utilizing mHealth technology have shown potential as important tools for
disease management. To date, one pilot study has examined the effects of an eHealth
intervention with a mHealth component in an attempt to control MetS risk factors and
thus, prevent disease progression [116]. The study enrolled 226 workers with at least one
MetS risk factor according to ATPIII guidelines. The workplace eHealth program
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consisted of a four-week education module (60 minutes per session) plus access to
telephone counseling, SMS messages and/or email messages for six months.
Additionally, pedometers were used to record daily step counts and BP monitors and
body fat scales were available in “eHealth zones”, which were installed in each
participating workplace, to measure BP twice daily and body fat once weekly. SMS
messages were sent once weekly to counsel regarding mean step counts, BP and body fat
or to follow-up when BP exceeded a threshold limit of 160/100 mmHg. Emails were sent
monthly with a summary of readings. Following six months, WC, SBP, DBP and TG
were reduced, with no changes in HDL [116]. FPG was also reduced, though only in the
group that started with MetS, not in the group with less than three MetS risk factors at
screening [116]. Additionally, the number of risk factors was reduced at follow-up – nine
percent of the population ended the study with zero risk factors, whereas everyone
commenced the study with at least one. In summary, this six-month eHealth intervention
improved MetS risk; however, it was limited to a population of workers whose employers
accepted the Healthy Workplace Program. Additionally, FPG was not monitored, despite
the relative ease of obtaining those measures. Future research is needed to examine the
efficacy of a mHealth intervention aimed at home monitoring and management of risk
factors, which would allow for the inclusion of a broader population.
1.5 Thesis overview
The overall objective of this thesis was to examine relationships between MetS risk
factors and HRV parameters. This was accomplished both cross-sectionally, by
examining associations between MetS components and HRV, and longitudinally by
investigating associations between changes in MetS components and changes in HRV in
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response to a novel intervention combining exercise prescription in primary care with a
mHealth home monitoring intervention for reducing cardiovascular risk. It was
hypothesized that HRV parameters would be associated with MetS risk factors.
Additionally, it was hypothesized that both MetS and HRV would be improved with a
mHealth-supported exercise intervention and that the changes in HRV will be associated
with changes in MetS risk factors.
Chapter 1 has provided basic background information on HRV and MetS. A literature
review examining the effects of lifestyle intervention, primarily increased physical
activity and exercise, on modification of MetS risk factors and HRV suggests that there
may be a link between the two cardiovascular risk factors. While exercise is known to
improve cardiovascular risk, a large proportion of the population does not engage in
sufficient amounts of physical activity to get full benefits. This chapter also examined
the potential of written exercise prescription in primary care settings or mHealth
supported interventions for health promotion.
Chapter 2 is a systematic review to synthesize the cross-sectional evidence to date that
has examined differences in HRV in populations with or without MetS and/or
associations between HRV parameters and MetS risk factors. This study found that HRV
was lower in women with MetS compared to those without, but that findings in men were
mixed. One study included in the review suggested that autonomic dysfunction may be
the factor responsible for insulin resistance, as alterations in HRV (SDNN and α1) were
seen in persons with one or more risk factors, while alterations in insulin resistance were
not apparent until at least two risk factors were present [52]. The review concluded that
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more rigorous analysis was needed in future examinations to gain greater understanding
of potential mechanisms associated with autonomic dysfunction in MetS.
Chapter 3 is a cross-sectional investigation of associations between HRV parameters and
MetS risk factors. As hypothesized, autonomic impairment (demonstrated by reduced
HRV) was generally seen in women with MetS, but not men. Multiple linear regression
models were run with and without insulin resistance included to determine whether it
strengthened the predictive model. Insulin resistance was associated only with HR,
which may be reflective of sympathetic activity in MetS populations. While these
findings suggest that insulin resistance contributes to sympathetic hyperactivity, but not
impaired vagal function in MetS, cross-sectional studies do not allow for conclusive
findings, and longitudinal studies are needed.
Chapter 4 is a pilot study to test the feasibility of a mHealth intervention to increase
physical activity and improve the cardiometabolic risk profile in a rural population. This
eight-week study proved that the technology was acceptable and feasible for participants
and researchers. Additionally, despite the short intervention period, fitness and some
MetS risk factors were improved and HRV was modified. However, due to the singlesample design of the study, it cannot be concluded that the mHealth support provided any
additional benefit to the exercise prescription.
Chapter 5 sought to examine longitudinal associations between changes in HRV
parameters and MetS risk factors caused by increased physical activity. To promote
increased activity, a randomized controlled trial was run comparing a mHealth
application to support increased physical activity to standard of care exercise
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prescription. Only changes in HR, SDNN and α1 were associated with changes in MetS
risk factors.
Chapter 6 summarizes the overall thesis and provides direction for future research and
knowledge translation activities.
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CHAPTER 2
Heart Rate Variability and the Metabolic Syndrome – A Systematic Review
2.1. Introduction
Metabolic syndrome (MetS) is a clustering of risk factors that increases the relative risk
of developing cardiovascular diseases (CVD) and type 2 diabetes mellitus (T2D) more in
combination than the simple addition of individual risk [1]. CVDs are the leading cause
of mortality worldwide [2] and it has been suggested that management of MetS risk
factors could substantially reduce risk [3]. Cardiac autonomic function, which can be
measured non-invasively with heart rate variability (HRV), has been suggested as a
potential mechanism underlying the development of MetS and CVD because of its
predictive power [4]. Autonomic dysfunction characterized by reduced HRV is
predictive of development of coronary heart disease [4,5] and T2D [6,7] and of all-cause
and cardiac mortality [8,9]. From this perspective, HRV could be a valid tool for
monitoring the progression of CVD.
To gain insight into the potential relationship between autonomic function and
development of CVD, a number of cross-sectional studies have examined relationships
between HRV and MetS [10-23]. Studies have examined differences between HRV in
individuals with (MetS+) or without MetS (MetS-) and have investigated associations
between HRV parameters and individual MetS risk factors. A number of different MetS
definitions, data collection protocols and analyses have been used, which makes
interpretation of results difficult. Therefore, the purpose of this systematic review was to
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describe the evidence in the literature examining relationships between HRV and MetS
and to provide recommendations for future studies.
2.2. Methods
2.2.1 Study Inclusion/Exclusion Criteria
The population of interest was adults aged ≥ 18 years. Studies were required to utilize
one of the major MetS definitions [24-27] – therefore, the search was limited to the years
1999 (following publication of WHO guidelines) to 2012. Studies were included if they
examined differences in standard HRV parameters [time domain (standard deviation of
normal to normal RR intervals (SDNN), root square mean of successive differences
(RMSSD); frequency domain (ultra low (ULF: 0-0.003Hz), very low (VLF: 0.0030.04Hz), low (LF: 0.04-0.15Hz) and high (HF: 0.15-0.4Hz) frequency and total power
(TP)) or non-linear (Poincaré plot standard deviation of instantaneous (SD1) and
continuous variability (SD2); detrended fluctuation analysis short-term scaling exponent
alpha (α1); beta-index (β) and approximate entropy)] between MetS+ and MetS-, or if
they examined associations between HRV and the overall number of MetS components
present or between HRV and individual MetS risk factors. Studies were limited to those
examining humans. Only papers published in English were included in this review.
2.2.2 Search Strategy
EMBASE and PubMed (1999-December 2012) databases were searched for articles with
the key words “heart rate variability” and “metabolic syndrome”. In press articles that
could be accessed electronically ahead of print were searched and included in the review.
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Reference lists of included papers were examined to select papers that were not identified
through database searches.
2.2.3 Quality Appraisal
Articles were reviewed and scored with a Downs and Black scale [28] modified to be
appropriate for the cross-sectional studies included in this review. A maximum score of
17 was attainable. Data were extracted (with a form created specifically for this review)
on sample size, population demographics, HRV analysis details, MetS classification,
HRV in MetS+ versus MetS-, HRV associations with the number of MetS components
and with each MetS risk factor – that is, waist circumference (WC), systolic and diastolic
blood pressure (SBP; DBP), fasting plasma glucose (FPG), triglycerides (TG) and high
density lipoprotein cholesterol (HDL). Authors were contacted in an attempt to clarify
data, when needed.
2.3. Results
2.3.1 Identification of Studies
The initial search returned 72 articles. Twenty-five were excluded because they were
not original journal articles (i.e. review papers, editorials, letters, notes or abstracts) and
twelve were duplicates across databases. Therefore, 35 abstracts were reviewed.
Seventeen papers were excluded from the review because analysis did not examine
associations between MetS and HRV directly (n=6), experimental design was
longitudinal and cross-sectional analyses were not included (n=5), the population did not
meet inclusion criteria (due to disease, age or MetS definition that was not standard)
(n=4), or heart rate parameters other than standard measures of variability were examined
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(n=2). Eighteen full-text articles were reviewed. Four papers were excluded because
standard MetS definitions were not used (n=2), HRV analyses were not standard (n=1),
or associations between MetS and HRV were not directly examined (n=1) (Figure 1).
2.3.2 Summary of Included Studies
The 14 studies included in the review are summarized in Table 2.1. Quality scores
ranged from 7-14 out of a maximum of 17. Despite known sex differences and age
effects, not all studies adjusted for these variables. Only three studies separated analysis
by sex [10,13,17] and three study populations included only males [11,14,15].
Additionally, heart rate (HR) is known to affect HRV and only one study included an
adjustment for this variable [17].
Most studies analysed short-term HRV over a period of three [17] or five [10-13,15,1820,22] minutes. The ECG recording was collected in the supine [10-13,17,22] or seated
position [18-20], or unspecified [15]. One study did not describe short-term HRV
analysis – therefore, only 24h HRV from this study was included in this review [21].
Five studies analysed HRV over a 24hr period, four in free living conditions
[10,16,21,23] and one under more stable conditions in a laboratory [14]. Since short- and
long-term HRV are not directly comparable, these analyses will be considered separately
in this review.
2.3.3 Heart rate variability according to metabolic syndrome status
Table 2.2 summarizes the eight studies that examined differences in short-term HRV
between MetS+ and MetS- [10-13,17-21]. Scores ranged from 7-14.
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Figure 2.1: Study flow diagram
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Table 2.1: Summary of literature included in the review
Age
Country
Range
(y)

Population

MetS
definition

HRV
analysis

Older adults

ATPIII

24 h &
5 min

ATPIII

5 min

General
population

ATPIII

5 min

Taiwan

Intellectual
disabilities

ATPIII

5 min

United
States

Veteran men

AHA

24 h

Reference

Score

N

Assoumou et al,
2010 [10]

13

1101 ~65

France

Brunner et al,
2002 [11]

10

183

United
Working men
Kingdom

Chang et al,
2010 [12]

14

1298 ≥20

Taiwan

Chang et al,
2012 [13]

7

129

19-62

Gehi et al, 2009
[14]

13

288

45-60

45-63

Hemmingway et 10
al, 2005 [15]

2197 45-68

United
Working Men
Kingdom

ATPIII

5 min

Jarczok et al, (in 13
press) [16]

2441 17-65

Germany Industrial
workers

Harmonized

24 h

Koskinen et al,
2009 [17]

11

2283 24-39

Finland

Young adults

ATPIII,
IDF

3 min

Lee et al, 2011
[18]

7

1027 NR

South
Korea

Adults with
Schizophrenia

ATPIII

5 min

Min et al, 2009
[19]

12

986

20-87

South
Korea

General
population

ATPIII

5 min

Min et al, 2008
[20]

12

1041 20-87

South
Korea

General
population

ATPIII,
IDF

5 min

RasicMilutinovic et
al, 2010 [21]

10

47

NR

Serbia

Aged <65y

ATPIII

24 h &
5 min

Soares-Miranda
et al, 2012 [22]

11

163

18-21

Portugal

Young adults

ATPIII,
IDF

5 min

Stein et al, 2007
[23]

12

1267 >65

United
States

Older adults

ATPIII

24 h
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Table 2.2: Summary of investigations examining heart rate variability alteration in
metabolic syndrome.
Reference
Short-term HRV
Assoumou et al,
2010 [10]

MetS+ compared to MetSTotal Population
Men

Women

↓TP, VLF, LF,
LF/HF, LFnu, HFnu

NS

↓LFnu, LF/HF

Brunner et al, 2002
[11]

NR

↓SDNN, TP, LF,
HF

NR

Chang et al, 2010
[12]

↓SDNN, HF, LF

NR

NR

Chang et al, 2012
[13]

NS

NS

↓TP, VLF, LF

Koskinen et al, 2009 NR
[17]

↓HF
↑LF/HF

↓HF, HFnu
↑LFnu, LF/HF

Lee et al, 2011 [18]

Schizophrenia – NS
Healthy - ↓SDNN,
RMSSD, LF, HF

NR

NR

Min et al, 2009 [19]

↓SDNN, HF, LF

NR

NR

Min et al, 2008 [20]

↓SDNN, HF, LF

NR

NR

24h HRV
Assoumou et al,
2010 [10]

↓TP, ULF, VLF, LF

NS

↓TP, VLF

↓TP, VLF, LF

NR

Gehi et al, 2009 [14] NR

Rasic-Multinovic et ↓HF, ↑LF/HF
NR
NR
al, 2010 [21]
HF – high frequency; HFnu – high frequency, normalized units; HRV – heart rate
variability; LF – low frequency; LFnu – low frequency, normalized units; MetS+ - with
metabolic syndrome; MetS- - without metabolic syndrome; NR – not reported; NS – not
significant; RMSSD – root mean square of successive differences; SDNN – standard
deviation of normal-to-normal intervals; TP – total power; ULF – ultra low frequency;
VLF – very low frequency.
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The six studies that scored highest (10-14) showed HRV differences in MetS+ and MetSwomen. Three studies showed that in a general population, SDNN, HF and LF were
reduced in MetS+ compared to MetS- [12,19,20]. Two large studies, one of older adults
(aged 65.6y) [10] and one of young adults (aged 29-34) [17] showed that some HRV
parameters were altered in MetS+ compared to MetS- women, but both showed no
differences in men. Young MetS+ women had reduced HFnu and increased LFnu and
LF/HF [17], while older MetS+ women had reduced LFnu and LF/HF [10]. Contrary to
these results, in a smaller cohort of middle-aged men (aged 45-63y) SDNN, TP, LF and
HF were reduced and HR increased in MetS+ compared to MetS-, with no differences in
LF/HF [11].
Two lower scoring studies (7) examining more specific populations showed similar
results. There were no differences in HRV in MetS+ compared to MetS- in male adults
with intellectual disabilities, although MetS+ women with intellectual disabilities had
reduced TP, VLF and LF [13]. There were no differences in MetS+ versus MetS- in
schizophrenics, but in healthy adults, MetS+ showed reduced SDNN, RMSSD, LF and
HF [18].
Three studies examined 24h HRV differences between MetS+ and MetS- [10,14,21]
(Table 2.2), all of which received moderate-to-high scores (10-13). Two studies
examined middle-aged (aged 46-60y) [14] or older adults (aged 65.6y) [10] and showed
reduced TP, VLF and LF in MetS+ with no differences between HF or LF/HF. ULF was
reduced in older adults with MetS [10], but not in the population of all males [14]. In a
small sample of the general population aged less than 65y, lnHF was reduced and
lnLF/HF was increased in MetS+ compared to MetS- [21]. Night-time HRV was
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reported in one study, which showed that TP, VLF, LF, LF/HF and LFnu were reduced
and HFnu increased in MetS+ compared to MetS- [10].
2.3.4 Heart rate variability and the number of metabolic syndrome components present
Four studies described changes in short-term HRV parameters with increasing number of
MetS components [10,12,17,20]. All scored moderate-to-high on the modified Downs
and Black scale (11-14). Chang et al. [12] showed that SDNN was reduced when one or
more risk factors were present compared to zero risk factors. Two studies showed that
there were no differences in frequency domain measures of HRV until at least three MetS
risk factors were present [10,12]. Min and researchers [20] reported reductions in HRV
with increasing number of MetS components, but did not report p-values, so significance
is unknown. Koskinen and colleagues [17] showed that the number of MetS components
present was indirectly related to HF, LF and TP and directly related to LF/HF; however,
after adjustment for age and resting HR, the inverse relationship to HF and relationship to
LF/HF persisted in women only.
The relationship between number of MetS components and HRV was also described by
three high scoring (12-13) studies that examined 24h HRV [10,14,23]. One study
examined the association between HRV and the number of MetS risk factors present, in
which all HRV parameters except for HF were associated with the number of
components [10]. Another study reported on differences between the presence of 0, 1, or
≥2 components [23]. SDNN, TP and ULF were lower in individuals with 2 or more
components compared to those with 0 or one component [23]. α1 was reduced in
individuals with 1 or ≥2 components compared to those with 0 components, but there

47
were no differences between those with 2 and those with 1 components [23]. In older
men, it was reported that individuals with all 5 components had an 18-50% reduction in
HRV values compared to those with zero risk factors and that each one unit increment in
the number of risk factors present reduced VLF by 8% and LF by 15% [14].
2.3.5 Associations between heart rate variability and individual metabolic syndrome risk
factors
Table 2.3 summarizes the six short-term and four 24h HRV studies that used regression
or correlation to investigates associations between HRV parameters and MetS risk
factors.
2.3.5.1 Heart rate variability and waist circumference
Three moderate-to-high scoring studies (11-13) examining large populations showed
associations with WC [10,17,20]. WC was negatively associated with SDNN, VLF, LF,
HF [20], LF/HF and LFnu [10]. Sex differences were present and conflicting. One study
of older adults showed that WC was negatively associated with LF/HF and LFnu in
women, but no associations in men [10], while a study of young adults showed WC to be
associated with reduced HF, LF and TP in men with no associations in women [17].
These relationships persisted after adjustment for age and HR. Three low-to-moderate
scoring studies (7-11) also showed equivocal results [13,15,22]. There were no
associations between WC and HRV in young adults aged 18-21 [22], but in women with
intellectual disabilities, increasing WC was associated with reduced VLF and LF/HF
[13]. In a large cohort of men aged 45-68y, WC had strong inverse relationships with

48
Table 2.3: Summary of investigations examining associations between HRV and
individual MetS risk factors.
Reference
↑ WC
Short-term HRV
Assoumou et
Men: NS
al, 2010 [10]
Women:
↓LFnu, LF/HF
All: ↓LFnu,
LF/HF

↑ BP

↑ FPG

↑ TG

↓ HDL

NS

NS

NS

Men: ↓TP,
VLF
Women:
↓LFnu,
LF/HF
All: ↓LFnu,
LF/HF

Chang et al,
2012 [13]

Men: NS
Women:
↓VLF, LF/HF

NS

Men: NS
Women:
↓TP, HF

Men: ↓TP,
VLF, HF
Women: NS

Men:
↓LF/HF
Women: NS

Hemmingway
et al, 2005
[15]

↓SDNN, HF,
LF, ↑HR

↓SDNN,
HF, LF,
↑HR

↓SDNN,
HF, LF,
↑HR

↓SDNN,
HF, LF,
↑HR

↓SDNN,
HF, LF

Koskinen et al, Men: ↓TP, LF,
2009 [17]
HF
Women: NS

Men &
Men: NS
Women:
Women:
↓TP, LF,
↓HF
HF, ↑LF/HF

NS

NS

Min et al,
2008 [20]

↓SDNN, HF,
LF

↓SDNN,
HF, LF

↓SDNN,
HF, LF

↓SDNN,
HF, LF

NS

SoaresMiranda et al,
2012 [22]

NS

SBP:
↓SDNN,
RMSSD,
HF, SD1,
↑HR

↓HFnu,
↑LF/HF

↓HF, HFnu,
↑LF/HF,
HR

NS

NS

Men: ↓TP,
LF, HF
Women: NS
All: ↓TP

Men: NS
Women:
↓HF,
↑LF/HF
All: ↓HF

Men: ↓TP,
ULF, VLF,
LF, HF
Women: NS
All: NS

Men: NS
Women:
↓TP, ULF,
VLF, LF
All: ↓TP,
ULF, VLF,
LF

↓LF

↓VLF, LF

↓LF

↓ULF, VLF, NS
LF, TP

24h HRV
Assoumou et
al, 2010 [10]

Gehi et al,
2009 [14]
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Table 2.3 continued
Jarczok et al
↓SDNN,
(in press) [16] RMSSD, LF,
HF

↓SDNN,
RMSSD,
LF, HF

↓SDNN,
RMSSD,
LF, HF

↓SDNN,
RMSSD,
LF, HF

↓RMSSD,
HF, ↑LF

Stein et al,
NR
NR
↓SDNN,
NR
NR
2007 [23]
VLF, ↑HR
BP – blood pressure; FPG – fasting plasma glucose; HDL – high density lipoprotein
cholesterol; HF – high frequency; HFnu – high frequency, normalized units; HR – heart
rate; HRV – heart rate variability; LF – low frequency; LFnu – low frequency,
normalized units; MetS+ - with metabolic syndrome; MetS- - without metabolic
syndrome; NR – not reported; NS – not significant; RMSSD – root mean square of
successive differences; SDNN – standard deviation of normal-to-normal intervals; TG –
triglycerides; TP – total power; ULF – ultra low frequency; VLF – very low frequency;
WC – waist circumference.
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SDNN, LF and HF [15]. In this study, the relationships between HRV and WC were
stronger than relationship between HRV and all other MetS risk factors [15].
Four studies examining 24h HRV scored 13 (high scores). One study showed that WC
was associated with all HRV parameters and that WC was the risk factor with strongest
associations [16], while another study showed no associations [10]. A study of males
showed that LF was reduced with increased WC [14]. When night-time HRV was
examined, WC showed no association with HRV [10].
2.3.5.2 Heart rate variability and blood pressure
Relationships between BP and short-term HRV are inconsistent in the literature. One
moderate-scoring study showed that HF, LF and TP were indirectly, and LF/HF directly
associated with SBP in men and women when adjustments were made for age, but when
HR was also adjusted for, only increased LF/HF was associated with increased SBP in
women [17]. A high-scoring study found that SDNN, VLF, LF and HF were negatively
related to both SBP and DBP [20], but a study of older adults showed no associations
between HRV and BP [10]. A moderate-scoring study of young adults showed SBP to be
associated with reduced SDNN, RMSSD, SD1 and HF and increased HR [22]. All HRV
parameters had strong linear associations with BP in men [15], but no associations were
seen in adults with intellectual disabilities [13].
24h HRV was generally associated with BP. One study demonstrated that all HRV
parameters were related with both SBP and DBP, although low HRV was more strongly
associated with DBP [16]. Another study showed that hypertension was negatively
associated with TP in older adults, but when sex differences were investigated,
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hypertension was negatively associated with TP, LF and HF in men, but there were no
associations in women [10]. One study reported that hypertension was associated with
VLF and LF in men [14]. Night-time HRV was not associated with BP [10].
2.3.5.3 Heart rate variability and fasting plasma glucose
Associations between FPG and short-term HRV vary. Three moderate-to-high-scoring
studies showed differing results. One showed that all HRV parameters were negatively
related to FPG [20], while another showed that FPG was associated with reduced HF in
women, but not in men [17]. However, when HR and age were accounted for, no
associations persisted [17], nor were there any relationships in older adults [10].
Moderate-to-low-scoring studies showed that increased FPG was associated with reduced
HFnu and increased LF/HF in young adults [22] and with reduced HF and TP in women
with intellectual disabilities [13]. In males, FPG had strong linear associations with all
HRV parameters [15].
In long-term HRV studies, multivariate analysis showed that increased FPG was
associated with reduced 24h RMSSD, SDNN, HF and LF and increased HR [16]. A
positive linear relationship was demonstrated between FPG and HR in the range of 4.46.4mmol/L and a negative linear relationship was shown between FPG and both SDNN
and VLF [23]. A study of older men showed that increased FPG was associated with
reduced LF [14], while another study showed no associations between FPG and HRV in
men, but negative and positive associations with HF and LF/HF, respectively, in women
[10]. One study showed no associations between night-time HRV and FPG [10], while
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another reported that increased FPG was associated with reduced RMSSD, SDNN, HF
and LF and increased HR [16].
2.3.5.4 Heart rate variability and triglycerides
Differing associations have also been shown between short-term HRV and TG. Two
moderate-to-strong studies reported no associations between TG and HRV [10,17],
though an inverse relationship in women was demonstrated following adjustment for age
and HR [17]. Another strong study with a broader population showed that all HRV
parameters studied (SDNN, VLF, LF, HF) were negatively related to TG [20].
Moderate-to-low scoring studies also showed varying relationships. In young adults, HF
and HFnu were indirectly and LF/HF and HR directly associated with TG [22]. Men
showed strong linear associations between TG and all HRV parameters [15], but men
with intellectual disabilities showed indirect associations only with HF, VLF and TP [13].
Long-term HRV studies also have had mixed findings. One study showed that TG was
associated with all HRV parameters studied [16], while another showed no associations
in the whole population or in women [10]. In men, TG was negatively associated with all
HRV indices except for LF/HF [10], or negatively associated with only ULF, VLF, LF
and TP [14]. There were no associations between day-time HRV and TG, but TG was
negatively associated with night-time TP, LF and HF in men [10]. There were no
relationships between night-time HRV and TG in women [10].
2.3.5.5 Heart rate variability and high density lipoprotein cholesterol
In most studies, HDL was not associated with any short-term HRV parameter
[15,17,20,22]. However, one strong study showed that LF/HF and LFnu were associated
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with HDL in the entire population and in older women and TP and VLF were associated
with HDL in older men [10]. Additionally, LF/HF was associated with HDL in men with
intellectual disabilities [13].
HDL was not associated with 24h HRV in men [10,14], but it was associated with all
HRV except SDNN in a general population [16], and with 24h TP, ULF, VLF and LF in
women [10]. HDL was negatively associated with night-time TP and VLF in the whole
population and with night-time VLF and LF in women, though there were no associations
in men [10].
2.4. Discussion
The key findings of this systematic review are that: 1) HRV generally is reduced in
MetS+ compared to MetS- in women, but results in men are inconsistent; 2) SDNN and
α1 are reduced with increasing number of MetS components present in an individual,
though differences for other HRV parameters may not be apparent until three MetS risk
factors are present; and 3) time and frequency domain HRV parameters are associated
with MetS risk factors and sex differences are apparent.
Most papers reported on standard frequency domain parameters of HRV. These findings
are important because frequency bands are thought to reflect different components of the
autonomic nervous system. A number of investigators have shown that the HF band is
reflective of parasympathetic activity, while the LF band reflects a combination of
sympathetic and parasympathetic activity and the LF/HF ratio is a measure of
sympathovagal balance [29]. Papers generally reported that HF and LF were reduced,
suggesting reduced vagal activity [11,17-20] and that in women, LF/HF was increased
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[10,17] suggesting altered sympathovagal balance. Both of these HRV states are
associated with poor health outcomes, though both lifestyle [30] and pharmacological
interventions [31] have shown promise in normalizing HRV in MetS patients.
Non-linear HRV analysis has been used in recent years to describe the qualitative, rather
than quantitative characteristics of heart rate. Only one short-term [22] and one longterm study [23] examined non-linear HRV. Soares-Miranda and colleagues [22]
reported that SD1 was reduced in young MetS+ adults compared to MetS-. SD1 is
considered to be primarily a measure of parasympathetic activity [32], and supports the
results from frequency domain HRV analysis. Stein and researchers [23] examined α1,
which describes the short-term scaling qualities of the heart rate signal. α1 was reduced
when one or more MetS components were present, suggesting that breakdown of fractallike R-R interval dynamics may be an early contributor to development of MetS and
subsequent CVD. The breakdown of fractal complexity occurs when there is a lack of
variability and when there is uncorrelated randomness [33]. Fractal breakdown has also
been associated with co-activation of the sympathetic and parasympathetic nervous
systems [34,35], which suggests that this pattern of autonomic regulation, which is unlike
the usual reciprocal interplay between the two autonomic nervous system branches, may
be an important mechanism in the progression to CVD. Reduced α1 has been shown to
predict arrhythmic and non-arrhythmic cardiac mortality in patients with depressed left
ventricular function following a myocardial infarction [36].
Despite these general conclusions, there were inconsistencies between studies. There are
a number of potential explanations for these mixed findings. Data collection methods
were not consistent between studies. Specifically, for the short-term data, some ECGs
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were collected while participants were seated and some were supine. Posture affects
HRV and results from the seated position are more reproducible [37]. Data were
generally collected for 5 min, though one study collected data for only 3 min. Perhaps the
most important contributor to differences in results was breathing rate during the data
collection period. Some studies required their participants to breathe at a constant rate in
time with a metronome, while others allowed free breathing. Respiratory sinus
arrhythmia is the primary contributor to the HF band of frequency domain HRV. In
persons with low breathing rates (less than 0.15Hz), this increase of power will show in
the LF band instead. Despite these methodological variances, differences in HRV
according to MetS status in women were consistently shown, while differences in men
were generally lacking.
The findings of this systematic review are important as they give insight into mechanisms
underlying the development of MetS and subsequently CVD and T2D. A review of
autonomic nervous system function in MetS showed that the individual risk factors –
obesity, hypertension, hyperglycemia and dyslipidemia – all were associated with
increased sympathetic and reduced parasympathetic activity [38]. It has been suggested
that autonomic alterations may precede risk factor development [4], and this is supported
by longitudinal studies which have found that individuals who developed CVD or T2D
over an observational study period generally had lower baseline HRV than those who did
not develop disease [5-7,39]. While this systematic review supports the hypothesis that
autonomic dysfunction is associated with MetS in women, the cross-sectional design of
the studies included does not allow causality to be inferred. Studies examining
differences in HRV according to presence of MetS risk factors could offer some insight

56
into causality on the premise that, if autonomic dysfunction precedes development of
MetS, it would be expected that HRV would already be reduced when only one or two
components were present compared to those with no risk factors. With the exception of
SDNN and α1, altered HRV was not apparent until three or more risk factors were
present. However, while this may suggest that HRV is not reduced until MetS is present,
it may be that those with lower HRV are more likely to accumulate three or more risk
factors, and therefore develop MetS compared to those with higher HRV, who may only
develop one or two risk factors. Robust longitudinal studies are needed for clarification.
Insulin resistance has been hypothesized as an underlying mechanism responsible for the
clustering of MetS risk factors in individuals [40]. Chang and colleagues [12] examined
the association of HRV and insulin resistance with the number of MetS components
present in an individual. They showed that HRV was already altered in persons with one
MetS risk factor, but insulin resistance was not apparent until two MetS factors were
present. Thus, it was suggested that autonomic modifications may precede changes in
insulin resistance. Interestingly, sympathetic hyperactivity is associated with insulin
resistance [41-43]. This suggests that one of the reasons for discrepancies in the
literature regarding associations between MetS risk factors and HRV may be the presence
of insulin resistance. Since all five components are associated with insulin resistance, it
may actually be insulin resistance and not the MetS risk factors per se that is responsible
for reductions in HRV. This may also explain the underlying mechanism for reduced
HRV in those with three or more compared to those with two or fewer components.
There is no previously published systematic review of the associations between HRV and
MetS. Robust methods were used for this review, which included strategies to further

57
seek out articles beyond simple database searches. However, articles were limited to
those published in English. Additionally, there is potential for publication bias. Studies
reporting non-significant differences between MetS+ and MetS- may not have been
accepted for publication, and therefore, lack of difference between MetS+ and MetS- may
be under-reported in the literature.
There were considerable differences between the studies included in this review, which
prevented meta-analysis. Differences in data collection, including patient position (i.e.
supine versus seated), breathing protocol (spontaneous versus paced), length of ECG
recording and type of HRV analysis all affect HRV, and therefore prevent data synthesis.
Since studies included in this review were cross-sectional in design, causality cannot be
inferred. Well designed longitudinal studies with robust measures and appropriate
control or adjustments for confounding variables are needed to examine associations
between HRV and the progression of cardiometabolic risk factors to CVD.
Few studies reported associations between MetS risk factors and non-linear HRV
parameters. Examination of these relationships could offer unique insight into
mechanisms underlying the development of risk factors and disease.
In conclusion, this systematic review of the literature showed that HRV is reduced in
women with MetS, though findings in men are inconclusive. Although HRV has been
shown to be reduced with increasing presence of MetS components, SDNN and α1 are the
only parameters that were reduced with fewer than three risk factors in combination.
Additionally, HRV is associated with all individual MetS risk factors, though
associations vary by population. Future studies should use consistent methods to allow
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for better comparability between studies. Additionally, more comprehensive analyses
should be performed to ensure that confounders are appropriately accounted for and to
investigate potential mechanisms.
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CHAPTER 3
Associations between heart rate variability, insulin resistance and metabolic
syndrome risk factors – a cross-sectional study
3.1 Introduction
Heart rate variability (HRV) has been utilized in the non-invasive assessment of cardiac
autonomic regulation. Alterations in HRV parameters including reduced standard
deviation of normal-to-normal RR intervals (SDNN) and reductions in the HRV spectral
frequency bands have been shown to predict cardiac and all-cause mortality in patients
with cardiovascular disease (CVD) [1,2] and in the general population [3,4].
Additionally, low HRV may predict the onset of coronary heart disease in individuals
with type 2 diabetes mellitus (T2D) [5]. The metabolic syndrome (MetS) is an important
clinical clustering of cardiovascular risk factors, which increases the risk of developing
CVD and T2D [6]. It is unclear whether a relationship between HRV and MetS could
provide an early marker of CVD and T2D risk.
The Cardiovascular Risk in Young Finns Study investigated the association between
three-minute supine HRV and MetS components (n=2283) [7]. This study showed that in
frequency domain analysis, the number of MetS components present was inversely
related to high- and low-frequency (HF, LF) and total power (TP) and directly related to
the LF/HF ratio in women [7]. This study was, however, limited to persons between the
ages of 24 and 39 years of age, so findings cannot be generalized to a broad population.
Min and colleagues [8] examined the relationship between five-minute seated HRV and
MetS in a sample of Korean men and women aged 20-87 years (n=1041). They found
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that the logarithmically transformed values of the SDNN, LF, HF and very low frequency
(VLF) were lower in those with MetS compared to those without MetS [8].
Each MetS component exhibits different associations with HRV parameters, though there
are many discrepancies between studies. Although there is no single risk factor that
appears to be consistently related to HRV, generally, waist circumference (WC), systolic
(SBP) and diastolic blood pressure (DBP), fasting plasma glucose (FPG) and
triglycerides (TG) have strong support from the majority of studies examining short-term
HRV [7-12], while high density lipoprotein cholesterol (HDL) has only shown
association with HRV in two studies [9,11]. Relationships between MetS, the individual
components of MetS and non-linear short-term HRV have only been examined in one
published study to date and this study only examined Poincaré plot parameters in a young
population aged 18-21 years [12]. To date, the relationship between other non-linear
parameters, including detrended fluctuation analysis short term scaling exponent (α1) and
approximate entropy (ApEnt), have not been examined in MetS, nor have Poincaré plot
parameters been examined in a more representative population of adults.
Insulin resistance has been implicated as an important mechanism linking the clustering
of MetS risk factors and autonomic dysfunction, ultimately leading to CVD and T2D
[13,14]. Chang and colleagues [15] noted that HRV was reduced in individuals with one
risk factor, but insulin resistance was not apparent until two risk factors were present.
However, the relationships between HRV, insulin resistance and MetS have not been
studied.
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Therefore, the purpose of this study was three-fold: first, to determine whether
individuals with MetS would have abnormal linear and non-linear HRV compared to
those without MetS; second, to determine which MetS risk factors were most strongly
associated with HRV parameters (both linear and non-linear); and third, to examine
whether insulin resistance was associated with HRV. It was hypothesized that all HRV
parameters would be reduced in MetS; that MetS risk factors except for HDL would be
associated with HRV parameters; and that insulin resistance would be associated with
HRV parameters.
3.2 Methods
This study was part of a multicentre trial conducted between August 2009 and December
2011 at the Gateway Rural Health Research Institute (Seaforth, Ontario) and the
Laboratory for Brain and Heart Health at Western University (London, Ontario).
Participants were eligible if they were aged 18-70 years and presented with at least one
MetS risk factor according to published guidelines [16]. Exclusion criteria were SBP >
180 mmHg and/or DBP > 110mmHg; type 1 diabetes; history of myocardial infarction,
angioplasty, coronary artery bypass or cerebrovascular ischemia/stroke; symptomatic
congestive heart failure; atrial flutter; unstable angina; unstable pulmonary disease; use of
medications known to affect heart rate (HR); second or third degree heart block; history
of alcoholism, drug abuse or other emotional cognitive or psychiatric problems;
pacemaker; unstable metabolic disease; and orthopedic or rheumatologic problems that
could impair the ability to exercise. In total, 224 participants (aged (mean±SD) 57.2±9.0
y, range 23-70y; 72% female) provided informed consent and volunteered for this study,
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which was approved by the University of Western Ontario Research Ethics Board
(#15828).
Participants reported to the laboratory following an overnight fast, where they were
assessed for MetS risk factors. WC was measured at the midpoint between the iliac crest
and last rib [17], and participants were considered at risk if WC was greater than 88cm
(women) or 102cm (men) [16]. Supine BP was calculated as the average of the last two
of three measurements taken at one minute intervals (BpTRU™, VSM MedTech Ltd.,
Coquitlam, BC or manual). A resting SBP ≥ 135 mmHg and/or DBP ≥ 85 mmHg
qualified as a MetS risk factor [16]. Blood was drawn and sent to a central laboratory for
FPG, TG, HDL and insulin analysis. MetS risk factors were FPG ≥ 6.1 mmol/L, TG ≥
1.7 mmol/L and HDL ≤ 1.03 mmol/L (men) or 1.29 mmol/L (women) [16]. Those
presenting with three or more risk factors were categorized as with MetS (MetS+), and
those with two or fewer risk factors were considered without MetS (MetS-) [16].
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated with
standard methods [18].
Following a light, standardized snack, participants were instrumented for collection of a
lead II ECG recording. A respiratory belt (Pneumotrace II, ADInstruments, Colorado
Springs, Colorado) was secured around the thorax for collection of respiratory rate. RR
intervals (RRI) were collected during ten minutes of supine rest. External stimuli, such
as light and noise were controlled to ensure signal stability. Participants were instructed
to remain still and awake. All measures were sampled at 1000Hz, input into a data
acquisition board (PowerLab ML795, ADInstruments) for analog-to-digital signal
conversion with LabChart7Pro software (ADInstruments) and stored for offline analysis.
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Lab Chart files were converted to text files for analysis with HRV software (Hearts v7,
Heart Signal Co., Oulu, Finland).
A predictive stepping test was used to estimate maximal oxygen uptake (VO2max). The
protocol has been published elsewhere [19]. Briefly, participants stepped up and down a
set of two 20cm stairs, 20 times, at a pace considered normal. Age, sex, body weight,
radial pulse measured immediately upon completing the step test and time to complete
test were entered into the predictive equation.
HRV Analysis
Editing of the HR time series was performed by a single investigator. All ECG signals
were manually scanned for ectopic or non-sinus beats, which were deleted from the time
series. 90% of data were needed for inclusion. Time domain HRV analyses included
HR, SDNN and the root square mean of successive differences (RMSSD). The HRV
spectrum was computed with the non-parametric fast Fourier transform method. LF
(0.04-0.15Hz), HF (0.15-0.4Hz), LF/HF and TP were examined. A Poincaré plot was
formed by plotting each RRI against the following one to create a scatter plot. The
standard deviation of the width (SD1) and length (SD2) were calculated. The detrended
fluctuation analysis method was used to examine fractal characteristics of heart rate
fluctuations. The root-mean square fluctuations of integrated and detrended data were
measured in observation windows and then plotted against the size of the window on a
log-log scale. α1 was calculated from the slope of the line (from 4-11 beats). ApEnt
quantifies the regularity of time series data by calculating the likelihood that runs of
patterns that are close will remain close on the next incremental comparison. A greater
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ApEnt value represents greater unpredictability in a system. ApEnt was calculated from
500 beats and was computed with length, m=2 and tolerance, r=20%
Statistical Analysis
In total, 23 participants were removed from analysis due to poor data quality, excessive
non-sinus rhythm beats or missing data. An additional four were removed from ApEnt
analysis as 500 heart beats were not available for analysis. Insulin was not analyzed in
28 participants, who were then excluded from analysis including HOMA-IR. Unpaired ttests were used to examine differences between normally distributed HRV parameters in
MetS+ versus MetS-. Welch’s correction was used for variables with unequal variance.
A two-sample Wilcoxon test was used when variables were not normally distributed.
Since sex differences have been demonstrated [7,9] analyses were run on the entire group
and separately for men and women. Multiple linear regression was used to determine
which components of MetS were associated with HRV parameters, while adjusting for
other variables. An a priori decision was made to force age, sex, study site and VO2max
into the model to account for potential confounding variables. All MetS components
were initially included in the model and the model was run using a backward elimination
model-building algorithm, with alpha set at 0.1, serially removing the least important
variable. Regression diagnostics were run to test for influential observations and outliers,
which were removed when necessary. To test associations with insulin resistance,
multiple linear regression models including HOMA-IR were completed as above. Data
are presented as mean ± standard deviation (SD) for normally distributed variables, as
median and interquartile range (IQR) for non-normally distributed variables, and as
regression coefficients (beta estimates) and 95% confidence interval (CI) for multiple
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linear regression results, unless otherwise stated. Statistical analysis was performed with
R Statistical Software (version 2.15.1) [20].
3.3 Results
Participant Characteristics
Participant characteristics are shown in Table 3.1. Age was similar in MetS+ and MetS-.
As expected, MetS+ had greater HOMA-IR, WC, SBP, DBP, FPG and TG, and lower
HDL compared to MetS-. Additionally, there were no differences in fitness. In women,
MetS+ had greater HOMA-IR, SBP, DBP, FPG and TG, and lower HDL compared to
MetS-, but there were no differences in WC. In men, TG was greater and HDL less in
MetS+ compared to MetS-, but there were no differences in HOMA-IR, WC, SBP, DBP
or FPG. VO2max was higher and HDL lower in men compared to women.
Heart rate variability in participants with or without metabolic syndrome
Overall, there were no differences in time domain HRV parameters between groups in the
whole population or in men. Time domain HRV analysis in women revealed that SDNN
was lower (38.0(27.0) ms, 44.5(29.3) ms; p=0.020) and HR higher (68(13) bpm, 64(12)
bpm; p=0. 018) in MetS+ compared to MetS-, but there were no differences in RMSSD.
After logarithmic transformation for normality, lnLF (5.81±1.09 ln ms2, 6.11±1.00 ln
ms2; p=0.044) was lower in MetS+ than MetS-, with no differences in lnHF, lnTP or
LF/HF. In men, there were no differences in frequency domain measures of HRV
between MetS- and MetS+. In women, lnLF (5.73±1.06 ln ms2, 6.13±1.05 ln ms2;
p=0.022) and lnTP (6.48±1.07 ln ms2, 6.87±1.04 ln ms2; p=0.030) were lower in
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Table 3.1: Participant Characteristics
MetS-

n

MetS+

p
(MetSvs
MetS+)

p
(Men vs
Women)

95
129
Men
21
41
Women
74
88
Age (y)
58(12)
59(10)
0.778
0.75
Men
57(12)
59(9)
0.451
Women
58(11)
59(11)
0.887
WC (cm)
103.3±14.6
107.3±11.1
0.036*
0.09
Men
105.6±13.0
109.0±10.6
0.307
Women
102.6±15.0
106.5±11.3
0.089
131(25)
135(17)
0.020*
0.84
SBP (mmHg)
135(22)
134(15)
0.914
Men
Women
130(23)
138(20)
0.014*
DBP (mmHg)
80±11
85±11
0.008*
0.06
Men
84±11
86±10
0.596
Women
79(11)
84(13)
0.009*
FPG (mmol/L)
5.1(0.8)
5.3(1.2)
0.018*
0.15
Men
5.4(0.5)
5.4(1.2)
0.726
Women
5.0(0.6)
5.3(1.2)
0.019*
0.16
TG (mmol/L)
1.01(0.56)
1.75(0.98)
<0.001*
0.002*
Men
1.13(0.63)
1.77(1.08)
<0.001*
Women
1.00(0.31)
1.75(0.93)
HDL (mmol/L)
1.57(0.50)
1.12(0.36)
<0.001* <0.001
Men
1.21(0.30)
0.96(0.21)
0.002*
Women
1.65(0.42)
1.19(0.31)
<0.001*
VO2max (ml/kg/min)
30.9±6.3
30.4±5.9
0.510
<0.001
Men
35.8±4.2
34.9±5.2
0.527
Women
29.6±6.2
28.3±4.9
0.146
HOMA-IR
1.56(1.19)
2.80(2.47)
<0.001*
Men
1.77(0.58)
2.95(2.59)
0.051
Women
1.33(1.23)
2.62(2.41)
<0.001*
DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density
lipoprotein cholesterol; HOMA-IR, insulin resistance; MetS-, without metabolic
syndrome; MetS+, with metabolic syndrome; SBP, systolic blood pressure; TG,
triglycerides;VO2max, maximum oxygen uptake; WC, waist circumference.
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MetS+ compared to MetS-, but there were no differences in lnHF, LF/HF (Figure 3.1).
Overall and in men, there were no differences in non-linear HRV parameters between
MetS+ and MetS-. In women, SD2 (46.8(31.6) ms, 58.4(29.9) ms; p=0.014) was reduced
in MetS+ compared to MetS-, but there were no differences in other non-linear HRV
measures (Figure 3.2).
Heart rate variability and metabolic syndrome components
Table 3.2 presents the results for each best-fit multiple linear regression model, including
predictors with alpha <0.1. All models were adjusted for age, sex, study site and fitness
and MetS components were tested for inclusion in the final models. For time domain
parameters, testing at a conventional alpha level of 0.05, only DBP was associated with
HR (p=0.010), although SBP remained in the model to improve the fit. TG was
associated lnSDNN (p=0.029), and both WC (p=0.037) and FPG (p=0.012) were
associated with lnRMSSD.
In the frequency domain, TG (p=0.047) and HDL (p=0.039) were associated with lnLF
and WC was associated with lnHF (p=0.024) and lnLF/HF (p<0.001). No MetS
components were associated with lnTP (p>0.05).
For non-linear HRV parameters, WC (p=0.030) and FPG (p=0.018) were associated with
SD1, and FPG (p=0.009), TG (=0.048) and HDL (p=0.002) were associated with SD2.
WC was associated with α1 (p=0.023) and FPG was associated with ApEnt (p=0.033).
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Figure 3.1: Differences in frequency domain heart rate variability. Black bars,
women without metabolic syndrome; white bars, women with metabolic syndrome;
striped bars, men with metabolic syndrome; dotted bars, men with metabolic
syndrome. * p<0.05 compared to women without metabolic syndrome.
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Figure 3.2: Differences in Poincaré plot variables. Black bars, women without
metabolic syndrome; white bars, women with metabolic syndrome; striped bars,
men without metabolic syndrome; dotted bars, men with metabolic syndrome.
* p<0.05 compared to women without metabolic syndrome.
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Table 3.2: Multiple linear regression results with metabolic syndrome risk factors
β

95% Confidence
Interval

p-value

F-statistic

Adjusted R2

HR
6.289
0.209
SBP
-0.053
(-0.006, 0.000)
0.062
DBP
0.009
(0.002, 0.016)
0.012*
lnSDNN
3.380
0.097
TG
-0.074
(-0.141, -0.008)
0.029*
HDL
0.358
(-0.011, 0.727)
0.057
lnRMSSD
3.556
0.125
-5
-5
-6
WC
-4.38x10
(-8.51x10 , -2.52x10 ) 0.037*
FPG
-0.260
(-0.462, -0.585)
0.012*
lnLF
3.106
0.087
TG
-0.152
(-0.303, -0.002)
0.047*
HDL
0.880
(0.043, 1.717)
0.039*
3.404
0.078
lnHF
-5
-5
-6
(-8.50x10 , -5.97x10 ) 0.024*
WC
-4.55x10
lnTP
4.553
0.082
TG
-0.125
(-0.271, 0.020)
0.091
2.877
0.079
LF/HF
WC
4.64x10-5
(1.95x10-5, 7.32x10-5) <0.001*
SBP
-2.34x10-4
(-5.08x10-4, 4.11x10-5) 0.095
lnSD1
3.436
0.110
-5
-5
-6
WC
-3.41x10
(-4.49x10 , -2.31x10 ) 0.030*
FPG
-0.125
(-0.229, -0.213)
0.018*
SD2
4.054
0.145
FPG
-4.798
(-8.387, -1.209)
0.009*
TG
-3.457
(-6.878, -0.035)
0.047*
HDL
30.847
(11.540, 50.152)
0.002*
α1
2.346
0.045
-5
-6
-5
WC
-1.07x10
(1.51x10 , 2.00x10 ) 0.023*
2.351
0.039
ApEnt
-3
-2
-4
FPG
-6.31x10
(-1.21x10 , -5.07x10 ) 0.033*
ApEnt, approximate entropy; α1, short-term scaling exponent; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; HF,
high frequency power; HR, heart rate; LF, low frequency power; RMSSD, root mean
square of successive differences; SBP, systolic blood pressure; SD1, Poincaré plot width;
SD2, Poincaré plot length; SDNN, standard deviation of normal to normal intervals; TG,
triglycerides; TP, total power; WC, waist circumference.
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Heart rate variability and insulin resistance
Table 3.3 shows multiple linear regression results with HOMA-IR included as a variable.
HOMA-IR was associated with HR (p=0.003) and improved the fit of the model
(Adjusted R2 0.220). The models for lnSDNN, lnLF and ApEnt were essentially
unchanged with the addition of HOMA-IR, while the inclusion of HOMA-IR in the
models for lnRMSSD, lnHF, lnTP, LF/HF, lnSD1, SD2 and α1 reduced the adjusted R2
value.
3.4 Discussion
The main finding of this study was that HRV profiles were less favourable in MetS+
compared to MetS-, and that differences existed in both linear and non-linear HRV
parameters in women, but not in men. Additionally, this study showed that HDL and TG
were associated with overall variability, but abdominal obesity and FPG were associated
with beat-to-beat HRV controlled primarily by the parasympathetic nervous system. This
study was the first to report that Poincaré plot analysis showed reduced parameters in
MetS+ compared to MetS- in women, but not men. SD2, which was reduced in women,
is considered a marker of long-term variation [21,22]. Physiological modelling showed
that the length of the Poincaré plot was correlated equally to both LF and HF spectral
powers, which suggests that it is affected by both sympathetic and parasympathetic input
[22,23]. Multiple linear regression showed that 14.5% of the variance of SD2 was
explained by FPG, TG and HDL in this population. There were no differences in SD1, α1
or ApEnt in MetS+ compared to MetS-. Interestingly, all of the non-linear parameters
that were not significantly different between MetS+ and MetS- were shown by multiple
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Table 3.3: Multiple linear regression results with metabolic syndrome risk factors
and HOMA-IR

HR
IR
SBP
DBP
lnSDNN
TG
HDL
lnRMSSD
TG
HDL
lnLF
SBP
DBP
TG
HDL
lnHF
lnTP
TG
LF/HF
WC
TG
lnSD1
TG
HDL
SD2
TG
HDL
α1

β

95% Confidence
Interval

p-value

1.298
-0.144
0.039

(0.460, 2.135)
(-0.247, -0.040)
(0.039, 0.409)

0.003*
0.007*
0.017*

-0.090
0.500

(-0.160, -0.022)
(0.057, 0.870)

0.011*
0.017*

-0.208
1.086

(-0.421, 0.005)
(-0.172, 2.344)

0.055
0.090

0.011
-0.021
-0.173
1.152

(-0.001, 0.022)
(-0.041, -0.001)
(-0.331, -0.016)
(0.233, 2.071)

-0.143

-8

Adjusted R2

6.550

0.220

2.822

0.092

2.260

0.053

3.138

0.097

3.200

0.047

3.262

0.064

1.876

0.056

2.310

0.055

3.478

0.111

1.524

0.012

0.069
0.039*
0.031*
0.014*

(-0.293, 0.006)
-5

F-statistic

0.060
-5

3.27x10
-1.57x10-2

(5.13x10 , 6.53x10 )
(-3.17x10-2, 4.84x10-4)

0.049
0.057

-0.104
0.535

(-0.210, 0.002)
(-0.095, 1.164)

0.055
0.096

-4.607
36.813

(-8.336, -0.879)
(14.917, 58.710)

0.016*
0.001*

ApEnt
1.873
0.028
HDL
-0.111
(-0.221, 0.002)
0.046
ApEnt, approximate entropy; α1, short-term scaling exponent; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; HF,
high frequency power; HR, heart rate; HOMA-IR, insulin resistance; LF, low frequency
power; RMSSD, root mean square of successive differences; SBP, systolic blood
pressure; SD1, Poincaré plot width; SD2, Poincaré plot length; SDNN, standard deviation
of normal to normal intervals; TG, triglycerides; TP, total power; WC, waist
circumference.
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linear regression to be associated with WC or FPG. For both MetS+ and MetS- groups,
mean WC was greater than sex-specific cut-offs for MetS risk, and mean FPG lower than
MetS thresholds. Hence, any alterations in these HRV parameters that would have been
attributed to increased WC as a MetS risk factor may have been equal in both groups.
The results of this study agree with most others that HRV is reduced in women with
MetS, but not in men [7,9]. However, some studies have shown alterations in HRV in
men with MetS [10]. In the present study, the only MetS risk factors that were different
between men with and without MetS were TG and HDL, with no differences between
WC, BP or FPG. Additionally, fitness (VO2max) was higher in men than women.
Therefore, the MetS+ men may have been healthier than the MetS+ women, which may
explain why HRV was not reduced in MetS+ men.
Generally, studies have shown that HRV analysed in both the time and frequency
domains are reduced in MetS, but differences exist regarding which parameters are
affected. One study showed that all time and frequency domain HRV was reduced in
MetS+ compared to MetS- with the exception of LF/HF [10], while others showed no
differences at all [11,24]. Another study showed that participants with MetS had
reductions in only SDNN, HF, LF and VLF [8]. This is similar to the present study,
which showed reduced lnSDNN and lnLF in MetS+ compared to MetS-, but there were
no differences in HF. These finding are important as two longitudinal studies of initially
healthy populations showed that reduced SDNN, lnLF and lnHF were associated with an
increased risk of developing coronary heart disease [25,26]. Frequency domain measures
and SDNN were primarily predicted by TG and HDL in this study, which suggests that
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management of dyslipidemia may be an important MetS treatment strategy to normalize
the HRV parameters that predict mortality.
In this study, lnHF, RMSSD and SD1 were not different between MetS+ and MetS-.
These HRV parameters are reduced or abolished with atropine administration, suggesting
a strong contribution from the parasympathetic nervous system [22,27]. Reduced HF is
predictive of mortality in healthy populations [25,26] and following myocardial
infarction [2]. Although there were no differences between groups in this study, both
groups had lower HRV than a healthy population [28]. Our population did not include
healthy people with no MetS risk factors. Therefore, parameters reflective of vagal
activity might actually be more sensitive to disease and the presence of one risk factor
may be sufficient to alter cardiac autonomic health. An alternate explanation may be that
our population was older (average aged 57.1years). Reductions in HRV parameters
reflective of vagal activity may have been due to age or other factors rather than presence
of MetS risk factors as the model to predict HF only explained 7.8% of the variance.
It is generally accepted that there is no HRV parameter that is reliably indicative of
sympathetic activity. A recent review of autonomic activity in MetS reported a strong
association between sympathetic activity and HR in a MetS population; hence authors
suggested that HR may be a valid surrogate measure of sympathetic activity [29]. In the
current study, MetS+ had a higher HR than MetS- in women. Though more research is
needed to confirm validity of the measure, this may suggest that sympathetic activity is
increased in MetS. Reviews of the literature have shown that sympathetic activity
measured by norepinephrine spillover and muscle sympathetic nerve activity is increased
in MetS [14,29,30]. It has been hypothesized that increased sympathetic activity in MetS
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may be associated with increased insulin resistance. In this population, both HR and
HOMA-IR were increased in MetS+ women but not in men. Interestingly, despite a
broad range of HOMA-IR, average HOMA-IR indicated normal insulin resistance in both
MetS+ and MetS-. This study does not support previous hypotheses that insulin
resistance was a mechanism involved in alterations in HRV in MetS [15]. Addition of
HOMA-IR to the multiple linear regression models generally reduced the adjusted R2
term, suggesting that it actually worsened the fit of the model. However, for HR and
lnLF– HRV parameters that arguably may be associated with sympathetic activity –
addition of HOMA-IR modestly improved the model. These findings suggest that
alterations in insulin resistance may be associated with increased sympathetic activity,
but findings do not support associations between insulin resistance and other HRV
parameters in MetS.
Potentially a significant contribution to the discrepancy in results may be that MetS
components may affect HRV to a different extent. Liao and researchers [31] showed that
in patients with multiple metabolic syndrome (defined as any combination of
hypertension, diabetes and dyslipidemia), there was a general reduction in HRV
parameters with an increasing number of metabolic disorders in a single individual (with
the exception of LF/HF, which showed no difference). However, there were differences
based on which metabolic risk factors were present. A combination of hypertension with
either dyslipidemia or diabetes had additive effects, while a combination of diabetes and
dyslipidemia had the lowest HRV, with more than simply additive effects [31]. Thus,
simply the presence (or not) of MetS may not be sufficient to cause alterations in HRV,
rather, specific combinations of risk factors may be a more important determinant.
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Since this was a cross-sectional study causality cannot be inferred. This study was
limited to a sample of relatively healthy adults – therefore findings may not be
generalizable to populations with overt disease. Participants were not restricted from
taking medications prior to ECG recording. Since certain anti-hypertensive medications
are known to improve HRV, these may have affected our results.
In conclusion, women with MetS have a less favourable HRV profile than women
without MetS, but these relationships were not apparent in men. There is no single MetS
risk factor that independently predicts all HRV parameters. Insulin resistance improves
model fit for HRV parameters that may be associated with sympathetic function, but not
for HRV parameters classically associated with parasympathetic function.
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CHAPTER 4
Diabetes and Technology for Increased Activity (DaTA Study): The effects of
exercise and technology on heart rate variability and metabolic syndrome risk
factors1.
4.1 Introduction
An increasingly aging, overweight and sedentary population has a greater risk of
developing cardiovascular disease (CVD) and type 2 diabetes (T2D). Metabolic
syndrome (MetS) is a clustering of risk factors including hypertension, dysglycemia,
dyslipidemia and abdominal obesity. Clustering of these factors doubles the five-year
risk of developing CVD and increases the risk of developing T2D five-fold [1]. Expert
panels have called attention to the importance of targeting the cardiovascular risk factors
of MetS in order to prevent CVD and T2D [1,2].
Heart rate variability (HRV) is a simple, non-invasive measure that can be used to
quantify autonomic nervous system function [3]. Diminished HRV predicts all cause and
cardiovascular mortality [4-7], and is associated with MetS risk factors [8-11]. In
patients with an increased risk of CVD, impaired autonomic function may be especially
dangerous. Patients with T2D with low HRV have double the risk of mortality compared

1

The results from this paper have been published: (1) Stuckey M, Fulkerson R, Read E, Russell-Minda E,
Munoz C, Kleinstiver P, et al. Remote monitoring technologies for the prevention of metabolic syndrome:
the Diabetes and Technology for Increased Activity (DaTA) study. J Diabetes Sci Technol 2011;5(4):936944. (2) Stuckey M, Russell-Minda E, Read E, Munoz C, Shoemaker K, Kleinstiver P, et al. Diabetes and
Technology for Increased Activity (DaTA) study: results of a remote monitoring intervention for
prevention of metabolic syndrome. J Diabetes Sci Technol 2011;5(4):928-935. They are reprinted here
with permission from the journal.
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to those with normal HRV [4]. There is evidence that lifestyle changes may have positive
autonomic effects [12-14], but these modifications may not be maintained long-term [15].
In Southwestern Ontario, cardiovascular risk is greater and access to healthcare is less in
rural communities compared to urban centres. The incidence of obesity, diabetes and
hypertension is higher in rural areas, specifically Huron County, compared to nearby
urban centres (London, Ontario) [16]. Additionally, Huron County has a 27.5% vacancy
rate for general and family practitioners compared to 0% in London and 20.2% vacancy
provincially in Ontario [17].
Remote monitoring technology has the potential to bridge the gap between healthcare
providers and patients in underserviced areas. Remote monitoring programs using
mobile telephones have effectively reduced individual risk factors in a number of studies.
Submitting home blood pressure (BP) measurements via short message service (SMS;
text messaging) and/or internet effectively reduced BP in uncontrolled hypertensive
patients [18] and obese hypertensive patients[19]. Patients with uncontrolled
hypertension who took BP measurements with a Bluetooth enabled BP monitor which
transmitted readings through a cellular telephone to a secure database monitored by
research personnel improved BP control in diabetics with uncontrolled hypertension [20].
Studies examining remote monitoring of blood glucose via cellular telephone to manage
diabetes have had promising, but mixed results. Some research found that glycated
haemoglobin (HbA1C) decreased [21-24], while one study showed no change [25].
Recent systematic reviews have examined the utility of remote monitoring technologies
for behaviour change in diabetic populations [26,27]. These papers agreed that one of the
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major shortcomings in the published literature was that the clinical outcome variable was
measured, but the intended behaviour change was not. Remote monitoring of behaviour
change concurrently with physiological measures would allow immediate data
assessment by practitioners and the ability to provide more appropriate, targeted feedback
to patients.
Therefore, the aims of this study were to investigate the feasibility and utility of using
remote monitoring technology to monitor home BP, blood glucose, HRV and physical
activity and to examine changes in home and clinic measures following an eight-week
lifestyle intervention. It was hypothesized that an intervention to increase physical
activity supported by home health monitoring technologies, would result in improvement
in risk factors for CVD and T2D, including MetS risk factors and HRV.
4.2 Methods
Twenty-five participants volunteered to participate in this study and provided informed
consent. Participants were included if they had at least two MetS risk factors according
to ATPIII guidelines: waist circumference (WC) ≥ 88cm (women) or 102cm (men);
resting systolic BP (SBP) ≥ 135 mmHg and/or diastolic BP (DBP) ≥ 85 mmHg; fasting
plasma glucose (FPG) ≥ 6.1 mmol/L; triglycerides (TG) ≥ 1.7 mmol/L; and high density
lipoprotein cholesterol (HDL) ≤ 1.03 mmol/L (men) or 1.29 mmol/L (women) [2].
Exclusion criteria were SBP > 180 mmHg and/or DBP > 110mmHg; type 1 diabetes;
history of myocardial infarction, angioplasty, coronary artery bypass or cerebrovascular
ischemia/stroke; symptomatic congestive heart failure; atrial flutter; unstable angina;
unstable pulmonary disease; use of medications known to affect heart rate (HR) (such as
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beta blockers), or use of other medication that may interfere with study objectives;
second or third degree heart block; history of alcoholism, drug abuse or other emotional
cognitive or psychiatric problems; pacemaker; unstable metabolic disease; and orthopedic
or rheumatologic problems that could impair the ability to exercise. One participant
withdrew from the study shortly following baseline testing due to hospitalization for a
respiratory illness unrelated to the study. Twenty-four participants (aged 56.6 ± 9.0y; 6
male) reported to Gateway Rural Health Research Centre at baseline (V0) and after four
(V1) and eight (V2) weeks of intervention. This study was approved by Institutional
Review Board Services (Aurora, Ontario, Canada; #RP-2008).
At each visit, BP was measured in the seated position with an automated BP cuff
(BPTru™, VSM MedTech Ltd., Coquitlam, BC). Clinic BP was calculated as the
average of the last two of three measures. Anthropometric measures included WC
measured as the midpoint between the lower rib and iliac crest (cm) [28]; body mass
index (BMI), calculated as weight in kilograms divided by the square of the height in
metres (kg/m2); and body weight (kg). Blood was drawn from the anticubital vein and
samples were sent to a central processing lab for analysis of FPG, lipid profile and
HbA1C.
An exercise specialist administered the Step Test Exercise Prescription (STEP™) to
estimate fitness (VO2max; ml/kg/min) and counsel participants regarding physical activity
[29]. Participants were instructed to step up and down a set of two steps twenty times at
a comfortable pace. HR was measured immediately following the test by palpation of the
radial artery and input into the prediction equation for calculation of VO2max (Appendix
1).
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A personalized exercise program was prescribed based on the fitness level determined by
the stepping test and a certified personal trainer helped participants set SMART (specific,
measurable, attainable, realistic, timed) goals. Exercise prescription followed American
College of Sports Medicine [30] guidelines, with a target exercise HR of 70-85% of age
predicted maximum HR. Goals included increasing pedometer-monitored steps per day
with the overall goal of achieving 10,000 steps per day [31]. The exercise prescription
and goals were updated at V1.
Home Monitoring
Participants received a smartphone (Blackberry® Curve 8300, Research in Motion,
Waterloo, Ontario) equipped with health monitoring software (Healthanywhere™,
IgeaCare Inc., Markham, Ontario), a Bluetooth™ enabled BP monitor (A & D Medical,
UA-767PBT, San Jose, California), a glucometer (Lifescan One Touch Ultra2™,
Milpitas, California, with wireless Bluetooth™ adapter Polymap, PWR-08-03, Tucson,
Arizona) and a pedometer (Omron, HJ-150, Koyoto, Japan). One-on-one technology
training was included at V0 and lasted approximately 30 minutes. Participants were
instructed regarding proper use of devices and techniques to get accurate measurements.
Blood glucose measures were to be submitted twice daily – fasted upon waking and nonfasted before bed, BP measures were to be submitted three times per week upon waking,
pedometer steps were to be input nightly, and body weight input weekly. Real-time
measurements were sent to a secure central database that was monitored regularly by
researchers. Limits were set for blood glucose at 3mmol/L and 15mmol/L, systolic BP
(SBP) at 60 mmHg and 210 mmHg and diastolic BP (DBP) at 40 mmHg and 120 mmHg.
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Readings that were outside of these limits triggered alarms that automatically sent a
message to the study physician’s smartphone to follow up with the participant.
During the week following V0 and V2 visits, participants received a HR and activity
monitor (Suunto Memory Belt, Vantaa, Finland), which was worn twice for five minutes
of seated rest and once for 24 hours. Data were downloaded from the monitor to a
personal computer and converted to text files for analysis (Heart Signal Co, Oulu,
Finland). Standard deviation of normal to normal R-R intervals (SDNN) was calculated
from the entire file for both five-minute and 24-hour recordings. Frequency domain
analysis was performed on the entire file for five-minute readings, and 24 hour HRV was
calculated as the average of one hour epochs. An autoregressive model (order 20) was
used to estimate power spectrum density for very low frequency (VLF: 0.003-0.04 Hz),
low frequency (LF: 0.04-0.15 Hz), high frequency (HF: 0.15-0.4 Hz) and total power
(TP: 0.003-0.4 Hz) [3]. Values were logarithmically transformed to attain normal
distribution. Fractal HR dynamics were calculated from the HR time series. This value
represents the qualitative characteristics and correlation features of HR behaviour. The
root-mean square fluctuations of integrated and detrended data were measured in
observation windows then plotted against the size of the window on a log-log scale. The
slope of the line was calculated (α1) to reflect short term HR behaviour. Recordings with
less than 80% qualifying beats were excluded from analysis.
Database and Data Security
Real-time data were transmitted from the smartphone to the server and database via
secure internet protocol. Personal identifiers were not stored in the Smartphone. All
communication of data between participant devices and the server were encrypted using
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secure sockets layer (SSL) certificates before storage. Data transfers between the
smartphones and the server were encrypted and only accessible using the Verisign
certified HTTPS session that employs SSL with a 128-bit encryption across all channels
for the Smartphone to server (key pair) and server to database. All data were encrypted
end-to-end according to the latest encryption standards and were authenticated and
checked for integrity to ensure that data was sent from an authorized source and had not
been tampered with. All clinical variables were transmitted as numbers only, were not
accompanied by identifiable information and were linked to participant data once on the
protected server.
Access to data was limited to authorized researchers with valid user identification and
passwords. If a smartphone was lost or needed to be replaced, safeguards (secure link)
were reprogrammed by changing the participant log in and password to ensure personal
health information was accessed by authorized personnel only. Healthanywhere accounts
were also controlled and protected remotely so that if a device was lost accounts were
deactivated to prevent unauthorized access to participant health information.
Statistical Analysis
SPSS software (Version 17) was used for analysis. Paired t-tests were used to observe
differences between V0 and V2 measures of BP, FPG, lipid profile, fitness,
anthropometrics and HRV. Paired t-tests were also used to examine changes in home
monitoring data from week 1 to week 8 (average of measures sent in week 1 and week 8,
respectively). Mean substitution was used for missing data. Pearson correlation was
used to determine whether any relationships existed between MetS risk factors and HRV.
All results are shown as mean ± standard deviation unless otherwise specified.
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4.3 Results
Participant characteristics are shown in table 4.1. At baseline, participants had 3.46 ±
1.22 of five metabolic risk factors (range 2 to 5). Based on ATPIII guidelines for MetS
[2], 95.8% of participants had abdominal obesity, 91.7% had high BP, 33.3% had
impaired fasting plasma glucose, 62.5% had high triglycerides and 62.5% had low HDL.
Six participants had T2D at study enrolment, and one was diagnosed with T2D shortly
after enrolment by remote monitoring blood glucose measurements and confirmed by
blood draw results.
Clinic DBP was reduced from 84±8 mmHg to 80±13mmHg (p=0.046) despite no change
in clinic SBP (V0: 141±10, V2: 139±19; p>0.05) (Table 4.2). However, the percentage
of participants with sufficient BP control, defined according to ATPIII criteria (clinic BP
less than 130/85 mmHg and not medicated for hypertension) increased from 8.3 to 33.3%
from V0 to V2. Similar to clinic BP results, there was no change in remotely monitored
SBP (Week 1: 136±17 mmHg; Week 8: 132±19 mmHg; p>0.05). DBP on the other hand
decreased from 88±12 mmHg in week 1 to 84±10 mmHg in week 8 (p<0.001) (Table
4.3).
There was no change in clinic (table 4.2) or home monitored blood glucose (table 4.3).
Likewise, there were no changes in triglycerides, LDL or HDL (table 4.2). Total
cholesterol decreased from 5.48±1.27 mmol/L at V0 to 5.19±1.11 mmol/L at V2
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Table 4.1: Participant Characteristics
Characteristics
n
Age
Number of males
Metabolic Syndrome Risk Factors (of 5)

24
56.6±8.9 years
6 (25%)
3.46±1.22

Above Metabolic Syndrome Thresholds:
Waist Circumference

95.8%

Blood Pressure

91.7%

Fasting Plasma Glucose

33.3%

Triglycerides

62.5%

High Density Lipoprotein Cholesterol

62.5%
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Table 4.2: Clinic values before and after the eight-week intervention
Clinic measure

V0

V2

p-value

111.5 ± 9.0

107.7 ± 11.6

0.002*

Systolic Blood Pressure (mmHg)

141 ± 10

139 ± 19

0.475

Diastolic Blood Pressure (mmHg)

84 ± 8

80 ± 13

0.046*

Fasting Plasma Glucose (mmol/L)

6.0 ± 2.4

5.5 ± 1.1

0.221

Triglycerides (mmol/L)

1.80 ± 1.32

1.53 ± 0.74

0.153

High Density Lipoprotein
Cholesterol (mmol/L)

1.34 ± 0.33

1.35 ± 0.40

0.655

Low Density Lipoprotein
Cholesterol (mmol/L)

3.14 ± 1.54

3.13 ± 1.07

0.983

Total Cholesterol (mmol/L)

5.48 ± 1.27

5.19 ± 1.11

0.009*

HbA1C (%)

6.0 ± 0.8

5.9 ±0.6

0.182

VO2max (ml/kg/min)

29.3 ± 5.6

34.7 ± 7.0

<0.001*

Waist Circumference (cm)
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Table 4.3: Home monitoring values during week 1 and week 8 of the eight-week
intervention
Home Monitoring Measurement

WEEK 1

WEEK 8

p-value

Systolic Blood Pressure (mmHg)

136 ± 15

133 ± 18

0.165

Diastolic Blood Pressure (mmHg)

88 ± 10

84 ± 9

<0.001*

Fasted Morning Blood Glucose
(mmol/L)

6.7 ± 2.4

6.3 ± 1.2

0.264

Non-Fasted Evening Blood Glucose
(mmol/L)

7.5 ± 2.8

6.9 ± 1.5

0.213

Pedometer Steps (steps/day)

5671 ± 1989

6757 ± 2455

0.003*

Body Weight (Kg)

92.7 ± 14.0

92.1 ± 13.8

0.312
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(p=0.009). Waist circumference decreased from 111.5±9.0 cm at V0 to 107.7±11.6 cm at
V2 (p=0.002), but there was no change in body weight (Table 4.3).
There was an 18% increase predicted VO2max from 29.34±5.60 ml/kg/min at V0 to
34.68±7.02 ml/kg/min at V2 (p<0.001). Pedometer steps increased from 5671±2670
steps/day in week 1 to 6757±3698 steps per day in week 8 (p=0.003).
Twelve participants had acceptable 24h HRV recordings both V0 and V2 (table 4.4).
HFnu increased from 24.5±12.0 at V0 to 28.0±12.1 at V2 (p=0.03) and LFnu decreased
from 75.5±12.0% at V0 to 72.0±12.1 at V2 (p=0.03) (Figure 4.1). There were no
changes in other 24h HRV variables. Thirteen participants had acceptable 5min HRV
recordings at both V0 and V2 (Table 4.5). There were no changes in 5min seated HRV
over the intervention period. DBP was correlated with 24h LF:HF (R=0.64). No other
relationships were seen between BP and HRV variables.
Compliance to the self-monitoring protocol was high with overall compliance of
96.8±4.0%. Compliance for BP readings was 95.0±14.1%; AM blood glucose
97.3±4.8%; PM blood glucose 97.8±4.7 %; pedometer steps 96.8±3.7%; and body weight
91.8±11.4%. A technology survey was administered at V2 to determine comfort with
technology and attitudes toward remote monitoring. Despite the fact that only four
participants had used smartphones prior to the study, only one participant was not
comfortable using the smartphone for study purposes. Using a likert scale from 1-4
(strongly disagree – strongly agree), it was noted that participants were comfortable with
the devices and that the remote monitoring protocol resulted in an increased sense of
security (3.58±0.50), assisted participants in adopting new practices to improve wellbeing
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Table 4.4: 24h heart rate variability (n=12)
V0

V2

p-value

RRI

822 ± 127

849 ± 131

0.288

HR

75 ± 11

72 ± 11

0.075

SDNN

150.3 ± 68.9

150.8 ± 57.9

0.962

lnLF

6.39 ± 0.78

6.41 ± 0.85

0.731

lnHF

5.18 ± 1.00

5.39 ± 1.09

0.107

3.9 ± 2.0

3.4 ± 2.6

0.223

1.367 ± 0.175

1.367 ± 0.171

0.982

LF/HF
α1

α1, short-term scaling exponent; HF, high frequency; HR, heart rate; LF, low frequency;
RRI, R-R interval; SDNN, standard deviation of normal to normal intervals; TP, total
power.
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*

Normalized Units

100

*

80
60
40
20
0
LF

HF

Figure 4.1: Changes in 24 hour LFnu and HFnu heart rate variability from V0
(black bar) to V2 (white bar). n=12; * p=0.03
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Table 4.5: 5min seated heart rate variability (n=13)
V0

V2

p-value

RRI

796 ± 147

867 ± 172

0.06

HR

78 ± 13

72 ± 13

0.10

58.6 ± 29.7

62.4 ± 32.6

0.70

LF

848.2 ± 1048.1

888.0 ± 1254.3

0.91

HF

307.6 ± 638.7

231.5 ± 359.7

0.67

5.8 ± 4.3

6.9 ± 7.8

0.60

1.388 ± 0.182

1.448 ± 0.205

0.10

SDNN

LF/HF
α1

α1, short-term scaling exponent; HF, high frequency; HR, heart rate; LF, low frequency;
RRI, R-R interval; SDNN, standard deviation of normal to normal intervals; TP, total
power.
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(3.83±0.38), did not take too much time (1.25±0.44) and did not interfere with activities
of daily living (1.33±0.48).
4.4 Discussion
The main finding of this study was that a technology driven, remote health monitoring
protocol was feasible in a rural population. Not only was the technology well accepted
by the participants, but it also resulted in improved fitness, WC, DBP and total
cholesterol. Furthermore, physical activity was increased and HRV was modified despite
the small sample size.
Previous studies using remote patient monitoring to control BP have primarily shown
better results than the current study with BP reductions of 9.1-11.0 mmHg SBP and 7.211.2 mmHg DBP [19,20]. This may be in part due to intervention methodology, as one
trial included weekly feedback with diet and activity recommendations via text message
[19]. Our participants received an updated physical activity prescription at V1, but the
weekly tailoring of lifestyle recommendations likely resulted in greater BP reductions.
The results of the current study were based on a small sample, in which two participants
had large increases in BP. Despite the fact that SBP was unchanged, the percentage of
participants with adequate BP control (defined by ATPIII MetS criteria < 130/85 mmHg
and not medicated for BP) increased from 8.3 to 33.3%. Additionally, it has been
estimated that even a small reduction in DBP of 2 mmHg would result in a 17% decrease
in the prevalence of hypertension, a 6% reduction in the risk of coronary heart disease
and a 15% reduction in the risk of stroke or transient ischemic attack [32]. Therefore, the
4 mmHg decrease in DBP in the current study may have clinical significance.
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Studies have reported either decreases [21-24] or no change [25] in HbA1C following
remote blood glucose monitoring interventions with cellular phones, but changes in
home-monitored blood glucose were not reported in these studies. The current study
showed no change in FPG, but baseline values were lower than in comparable studies and
the intervention period was shorter than other trials. Additionally, the American College
of Sports Medicine and American Diabetes Association joint position statement
recommends 150 minutes of moderate to vigorous activity per week to reduce blood
glucose [33]. Considering that the pedometer steps only increased 1086 steps/day,
participants may not have completed a sufficient amount of moderate to vigorous
physical activity to affect FPG levels.
Moderate intensity exercise is recommended as a first-line therapy for MetS [28]. A
recent study examined the effects of a four-week therapeutic lifestyle modification in
rural women with MetS and showed that the intervention group had significant reductions
in body weight, WC, TG, FPG, SBP and LDL and increased HDL [34]. These results
differ from ours and likely result from differences in intervention delivery. Oh and
colleagues [34] provided information booklets to participants at the onset of the trial and
the intervention group attended education and exercise sessions three times per week for
two hours each time. Education sessions included both nutrition and exercise advice. In
the present study tailored exercise prescription was provided, but the exercise was
unsupervised and dietary advice was not given. Tjønna and colleagues [35] noted greater
improvements in MetS in a group of patients completing high intensity interval training
compared to a continuous moderate exercise group, thus reinforcing that higher
intensities are better for reducing cardiovascular risk. Our participants were prescribed
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moderate intensity activity with a target HR of 70-85% of age-predicted maximum.
Greater improvements may have been elicited from higher intensity activities, but as our
participants were in an unsupervised setting, moderate intensity was chosen for safety.
Although only three participants achieved their step goal and averaged 10,000 steps/day
by week 8, the increase in PA (mean increase of 1086 steps/day) was sufficient to
improve markers of MetS. This was despite the fact that the population sample remained
classified as low active based on daily step count [31]. Individual exercise prescriptions
were tailored to include other activities as well as walking. Several participants
participated in physical activities that are not conducive to pedometer monitoring
including cycling, swimming, and resistance training. Therefore, activity may have
increased more than was measured by the pedometer. The fact that VO2max increased
18% (5.34 ml/kg/min) over an 8-week intervention period, suggests that activity levels
increased during the study. It is also possible that although the increase in steps per day
was small, the intensity at which the steps were taken may have been greater.
Participants were taught how to take their radial pulse and instructed to attain their target
HR (70-85% of age-predicted maximum) during exercise sessions. Unfortunately,
activity intensity was not measured by HR monitor or accelerometry, nor was it recorded
in an exercise journal.
HRV is an index of autonomic function that has been shown to be reduced in MetS [811]. Aerobic exercise training in hypertensives has been shown to improve HRV [1214], though changes in HRV tend to be more apparent during a stressor that induces
sympathetic stimulation and parasympathetic withdrawal, than during supine rest. Since
HRV in the current study was recorded during seated rest, subtle changes in autonomic
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function may have occurred that our experimental protocol was not sensitive enough to
detect. Since this feasibility study analysed home HRV measurements, the five-minute
HR recordings for seated HRV analysis were not performed under tightly controlled
laboratory conditions as recommended [3]. As variations in temperature, light,
movement and breathing frequency can all affect HRV [3], lack of control of these
factors may be responsible for the lack of change in short-term HRV.
Compliance to technology use was higher in this trial (96.79 ± 4.01%) than others
[21,24]. Compliance to a three-month intervention was only 72% [24], and only two of
fifteen patients submitted all blood glucose and pedometer readings in a three-month pilot
study [21]. In the present study, four of 24 participants completed all measures and 12
others missed less than five of an average 207 total readings. Discrepancies may be due
to longer intervention period [21,24] and broader age range [24] compared to the present
study. The high compliance in this trial may be explained by the age of our sample, as
older adults have been shown to have greater compliance than younger adults [24]. This
may be in part because of fewer commitments to care-giving and employment and greater
interest in disease prevention. The high compliance to this study may also be a result of
the short time period. A four-month study examining home BP monitoring found that
weekly compliance was high throughout, but tended to decrease in the last four weeks
[20]. The participants in the present study with lowest compliance were either shift
workers (n=2) or had family/care-giver commitments (n=1).
Other research has shown that one of the greatest barriers to the use of technology is the
time commitment by physicians to monitor the database [20]. Our study required less
physician intervention as triage of clinically important measurements was automated thus
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limiting physician burden. Participants also had access to their personal data throughout
the study that provided self-reflection, goal setting and self-motivation that served as
positive and negative support.
This pilot study was conducted in a sample of highly motivated volunteers and may
therefore lack external validation. Since there was no control group, it cannot be
concluded that improvements in health and activity were a result of self-monitoring
technologies. However, the purpose of this pilot study was to test the feasibility and
utility of a remote monitoring and activity protocol in a rural population. Future
randomized trials are needed to compare the impact of an exercise prescription alone with
that of an exercise prescription combined with self-monitoring. A baseline pedometer
measurement was not attained prior to exercise prescription. Therefore, it is likely that
habitual activity prior to the onset of pedometer monitoring was in fact lower than the
week 1 measurements obtained in this study. Despite the fact that only twelve
participants had acceptable HR data for 24h HRV analysis and thirteen for 5min HRV,
modifications were seen in LFnu and HFnu. However, a greater sample size would have
been ideal and may have shown greater change. The technology survey was not a
validated questionnaire. However, the responses will still be able to direct protocol
modifications to improve a larger trail.
In conclusion, an exercise prescription combined with eight weeks of self-monitoring of
health and activity measures resulted in increased fitness and activity, which improved
cardiovascular risk profile as demonstrated by reductions in WC, DBP and total
cholesterol and improved 24h HRV profile with increased HFnu and reduced LFnu.
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CHAPTER 5
Effects of a mHealth exercise intervention on heart rate variability and metabolic
syndrome risk factors in primary care.
5.1 Introduction
Cardiovascular diseases (CVD) are the leading cause of death world-wide [1] and type 2
diabetes mellitus (T2D) is an independent risk factor for CVD. In 2004, heart disease
was responsible for 68% and stroke was responsible for 16% of all deaths in patients
diagnosed with T2D in the United States [2]. Central obesity, high blood pressure (BP),
dysglycemia and dyslipidemia are some of the major cardiometabolic risk factors
implicated in the development of CVD and T2D [3,4]. Clustering of these risk factors,
termed metabolic syndrome (MetS) increases the risk of disease progression more in
combination than additive risk [3,4].
Mechanisms associated with the progression from MetS to T2D and CVD are poorly
understood. Autonomic dysfunction has been hypothesized to be an important
component of CVD progression [5,6]. Abnormal cardiac autonomic function, as
indicated by low heart rate variability (HRV), is associated with increased all-cause and
cardiovascular mortality in post-myocardial infarction patients [7,8] and with the
development of T2D in a general population [9,10]. Furthermore, individuals with T2D
and low HRV were more likely to develop CVD than those with normal HRV values
[11,12]. Low HRV is also characteristic of MetS populations [13]. Autonomic
dysfunction is consistently reported in females with MetS, while findings are more
controversial in males [14-16]. A systematic review showed that MetS risk factors are
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associated with different HRV parameters and suggested that impaired autonomic
function, or low HRV, may be an important mechanism in the continuum of CV risk [17].
However, to date studies are cross-sectional and associations between longitudinal
changes in MetS and HRV have not been examined.
Physical activity is recommended as a first line treatment for MetS [3,4]. Lifestyle
changes have proved to reduce disease progression [18,19] and long-term follow-up has
determined that lifestyle changes are more effective than metformin in reducing the
incidence of T2D [20]. Exercise also improves HRV in the general population [21,22]
and in T2D [23,24]. These concomitant improvements in MetS risk factors and HRV in
response to exercise suggest that they may be linked mechanistically. However,
longitudinal associations have not been examined.
Despite the well-known health benefits of physical activity, accelerometer data has
shown that 85% of Canadians [25] and 90% of Americans [26] do not meet national
physical activity guidelines. Electronic health (eHealth) is a relatively new field in which
electronic medium is used to support health. While studies are still in their infancy some
successes have been noted [27]. Mobile health (mHealth) is a branch of eHealth that has
the potential to be better than general eHealth interventions because of the portability.
Eighty-five percent of the American population owns a mobile phone, and in this group
Smartphone ownership has risen from 33% in May 2011 to 53% in November 2012 [28].
With the quickly growing number of smartphone users, mHealth interventions allow for
the potential to act as a trigger for behaviour or to provide information at the time that it
is needed. We recently showed that a mHealth supported exercise intervention increased
activity and improved MetS risk factors in a rural population [29]. Additionally,
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participants found the technology acceptable and motivational [30]. Despite a small
sample size and short follow-up period, improvements in 24h HRV were apparent
(unpublished data; Chapter 4). However, due to the single group design of the pilot
study, it is unknown whether the mHealth component had added benefit compared to the
exercise intervention alone.
The purpose of this randomized controlled trial was two-fold: 1) to examine associations
between longitudinal changes in HRV parameters and MetS components; and 2) to
isolate the mHealth component by comparing the effects of an exercise intervention
supported by mHealth technology to exercise prescription alone. We hypothesized that
changes in MetS components would be associated with changes in HRV parameters and
that the mHealth supported group would have greater improvements in MetS risk factors
and HRV than the control group.
5.2 Methods
This study was part of a 12-month randomized controlled trial, in which 149 participants
from rural Southwestern Ontario were block randomized to either the exercise
prescription plus mHealth technology intervention group (EX+T; n=75) or the exercise
prescription only active control group (EX-C; n=74). This paper reports interim results at
24 weeks. At screening, participants were required to have a minimum of two of five
MetS risk factors according to National Cholesterol Education Program – Adult
Treatment Panel III (ATPIII) criteria – waist circumference ≥ 88cm (women) or 102cm
(men); systolic blood pressure (SBP) ≥ 135mmHg and/or diastolic BP (DBP) ≥ 85
mmHg; fasting plasma glucose (FPG) ≥ 6.1 mmol/L; fasting triglycerides (TG) ≥ 1.7
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mmol/L; fasting high density lipoprotein cholesterol (HD) ≤ 1.29 mmol/L (women) or
1.02 mmol/L (men) [31]. Exclusion criteria were systolic blood pressure (SBP) > 180
mmHg and/or diastolic blood pressure > 110mmHg; type 1 diabetes; history of
myocardial infarction, angioplasty, coronary artery bypass or cerebrovascular
ischemia/stroke; symptomatic congestive heart failure; atrial flutter; unstable angina;
unstable pulmonary disease; use of medications known to affect heart rate (HR); second
or third degree heart block; history of alcoholism, drug abuse or other emotional
cognitive or psychiatric problems; pacemaker; unstable metabolic disease and orthopedic
or rheumatologic problems that could impair the ability to exercise. The study was
approved by the University of Western Ontario research ethics board (#15828) and
participants provided informed consent to participate.
Participants reported to the Gateway Rural Health Research Institute (Seaforth, Ontario)
at baseline (V0), 12 weeks (V1) and 24 weeks (V2). Automated BP was measured in the
supine position (BPTru™, VSM MedTech Ltd., Coquitlam, BC) and the average of the
last two of three measures was used to determine clinic BP. WC was measured as the
midpoint between the lower rib and iliac crest (cm) [32]. Blood was drawn and sent to a
central laboratory for measurement of FPG, TG and HDL.
Autonomic testing
Following a light, standardized snack, participants were instrumented for collection of a
lead II ECG (Colin Pilot 9200, Colin Medical Instruments, San Antonio, Texas) and
respiratory rate by belt transducer (Pneumotrace II, ADInstruments, Colorado Springs,
Colorado) secured around the thorax. Data were collected during ten minutes of supine
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rest. External stimuli, such as light and noise were controlled to ensure signal stability.
Participants were instructed to remain still and awake. All measures were sampled at
1000Hz, input into a data acquisition board (PowerLab ML795, ADInstruments) for
analog-to-digital signal conversion with LabChart7Pro software (ADInstruments) and
stored for offline analysis.
Exercise testing and prescription
Fitness (VO2max; ml/kg/min) was estimated with the Step Test Exercise Prescription
(STEP™) tool, which has been validated in adults aged 18-85y [33,34]. The full protocol
has been published elsewhere [35]. Briefly, participants were instructed to step up and
down a set of two steps twenty times at a comfortable pace. Heart rate (HR) was
measured immediately following the test by palpation of the radial artery and age,
weight, sex, time to complete test and post-test HR were used to calculate predicted
VO2max (Appendix 1). Fitness was classified by age, sex and VO2max as poor, fair, good
or excellent. A tailored exercise program including target HR based on fitness level
[poor =70% maximum age-predicted HR (HRmax); fair = 75% HRmax; good = 80% HRmax;
excellent = 85% HRmax] was prescribed based on the results of STEP™ and an exercise
specialist helped participants set SMART (specific, measurable, attainable, realistic,
timed) goals. For EX+T, goals included increasing steps per day with pedometer
monitoring, with the overall goal of achieving 10,000 steps per day. The exercise
program and goals were updated at each visit.
Mobile Health Intervention
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Participants received a smartphone (Blackberry Curve 8300 or 8530, Research in Motion,
Waterloo, ON) equipped with health monitoring application (Healthanywhere, BioSign,
Markham, ON), a Bluetooth enabled BP monitor (A & D Medical, UA-767PBT, San
Jose, CA), a glucometer (Lifescan One Touch Ultra2™, Milpitas, CA) with Bluetooth
adapter (Polymap Wireless, PWR-08-03, Tucson, AZ) and a pedometer (Omron, HJ-150,
Kyoto, Japan). A group training session (approximately two-hour duration) was
delivered at V0, during which participants were instructed on proper use of devices and
techniques to get proper measurements. FPG and BP measures were to be submitted
thrice weekly upon waking and pedometer steps were to be input nightly. Details of data
transfer, biometric thresholds for alerts and database security are reported elsewhere [30].
Heart rate variability analysis
R-R intervals (RRI) were extracted from continuous ECG recordings for analysis with
HRV software (Hearts v7, Heart Signal Co., Oulu, Finland). The HR time series was
edited by a single investigator. All ECG signals were manually scanned for ectopic or
non-sinus beats, which were deleted from the time series. Datasets were excluded from
analysis when more than 10% of beats were edited. Time domain HRV analyses
included HR, SDNN and the root square mean of successive differences (RMSSD). The
HRV spectrum was computed with the non-parametric fast Fourier transform method.
Low frequency (LF: 0.04-0.15Hz), high frequency (HF: 0.15-0.4Hz), LF/HF and total
power (TP: 0.003-0.4Hz) were examined [36]. These measures are repeatable over shortand long-term [37]. Each RRI was plotted against the following one to create a Poincaré
plot. The standard deviation of the width (SD1) and length (SD2) were calculated
[38,39]. The detrended fluctuation analysis method was used to examine fractal
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characteristics of heart rate fluctuations [40]. The root-mean square fluctuations of
integrated and detrended data were measured in observation windows and then plotted
against the size of the window on a log-log scale. The short-term scaling exponent (α1)
was calculated from the slope of the line (from 4-11 beats) [41].
Statistical Analysis
Baseline characteristics were compared between groups with unpaired t-tests for outcome
measures with normal distribution or a two sample Wilcoxon test for outcome measures
that were not normally distributed. Analysis of covariance (ANCOVA) was used to
examine differences in mean change between EX+T and EX-C for MetS risk factors,
fitness, HOMA-IR and HRV parameters with sex and baseline values as covariates. Age
was also included as a covariate for HRV parameters. Paired t-tests were used to
examine changes from V0 to V2 for the whole population when there were no differences
between groups for mean change, or for EX+T and EX-C separately when differences
were shown by ANCOVA. Multiple linear regression models were used to investigate
how changes in MetS components predicted changes in HRV, while adjusting for other
variables and baseline values. An a priori decision was made to force age, sex, group
and VO2max into the equation to adjust for potential confounders. Backwards elimination
was used to create the most appropriate model. All MetS components were originally
included in the model and the least important was serially excluded using the criteria
p<0.1. This strategy sought to identify a parsimonious set of predictors for the outcome
of interest. Upon completion of the initial model, diagnostics were run to test for
influential observations and outliers were removed when necessary. All results are
shown as mean ± standard deviation for normally distributed data, median (interquartile
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range; IQR) for non-parametric data, and multiple linear regression results are presented
as estimate (95% confidence interval; CI), unless otherwise specified. R statistical
software was used for analysis [42].
5.3 Results
Participant Characteristics
After removal of incomplete data, 116 participants (62 EX+T; 54 EX-C) were included in
the final analysis (Table 5.1). FPG (p=0.008) and HOMA-IR (p=0.010) were higher in
EX+T compared to EX-C, but groups were otherwise similar.
Longitudinal changes in metabolic syndrome risk factors and heart rate variability
parameters
There was no difference between groups in mean change for any MetS risk factor,
VO2max or HOMA-IR (p>0.05). Figure 5.1 shows changes in MetS risk factors over time.
WC (V0: 103.5±13.2 cm; V2: 99.7±12.4 cm; p<0.001), SBP (V0: 141±19 mmHg; V2:
131±15 mmHg; p<0.001) and DBP (V0: 86±11 mmHg; V2: 81±9 mmHg; p<0.001) were
reduced over time across the whole population with no differences between groups
(p>0.05). There were no changes in FPG (V0: 5.0(0.8) mmol/L; V2: 5.0(0.6) mmol/L),
TG (V0: 1.36 (0.96) mmol/L; V2: 1.32(0.91) mmol/L), HDL (V0: 1.40 (0.53) mmol/L;
V2: 1.38(0.51) mmol/L) or HOMA-IR (V0: 1.63(1.75); V2: 1.54(2.09)) over time
(p>0.05). VO2max increased in the whole population with no differences between
treatment groups (V0: 30.77±6.22 ml/kg/min; V2: 32.81±6.24 ml/kg/min; p<0.001).
RMSSD, lnHF and SD1 were reduced at V2 compared to V0 (p=0.048, 0.032 and 0.049,
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Table 5.1: Participant characteristics
Exercise + Technology

Exercise Only

62

54

Age (y)

58.0 (14.0)

59.5 (11.8)

0.482

WC (cm)

105.2±12.6

101.7±13.8

0.151

SBP (mmHg)

141±20

142±19

0.926

DBP (mmHg)

86±13

87±10

0.690

FPG (mmol/L)

5.1 (0.9)

4.9 (0.5)

0.013*

TG (mmol/L)

1.42(0.76)

1.31 (1.05)

0.791

HDL (mmol/L)

1.34 (0.57)

1.45 (0.47)

0.312

HOMA-IR

1.90 (1.66)

1.37 (1.01)

0.010*

30.0±6.3

31.4±6.3

0.236

N

VO2max (ml/kg/min)

p

DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density
lipoprotein cholesterol; HOMA-IR, insulin resistance; SBP, systolic blood pressure; TG,
triglycerides; VO2max, maximal oxygen uptake; WC, waist circumference.
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Figure 5.1: Changes in metabolic syndrome risk factors over time. A) waist
circumference, systolic and diastolic blood pressure; B) fasting plasma glucose,
triglycerides and high density lipoprotein cholesterol; at V0 (black bar) and V2
(white bar). * p<0.05
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respectively), but there were no other significant changes in HRV parameters over time
(Table 5.2).
Associations between changes in metabolic syndrome risk factors and heart rate
variability
Multiple linear regression (Table 5.3) showed that the change in HR and SDNN were
associated with the change in WC (p=0.033) and FPG (p=0.048), respectively. The
change in α1 was associated with the change in SBP (p=0.045) and TG was included in
the model to improve the fit (p=0.066). The change in MetS risk factors over the
intervention period were not associated with the change in HRV parameters RMSSD,
lnLF, lnHF, lnTP, LF/HF or SD1.
5.4 Discussion
The main findings of this study were that: 1) WC, SBP and FPG were the only MetS
components that independently predicted changes in HRV, and only changes in HR,
SDNN and α1 were associated with MetS component changes; 2) RMSSD, lnHF and SD1
were reduced following the intervention period with no other changes in HRV; and 3)
WC, SBP and DBP were reduced following the 24-week intervention with no change in
other MetS risk factors and no differences between treatment groups.
Previous studies have examined associations between HRV parameters and MetS risk
factors in cross-sectional studies [13-16]. To our knowledge, this was the first study to
examine these associations over a longitudinal intervention period. Interestingly,

119
Table 5.2: Changes in heart rate variability from baseline to 24 weeks
V0

V2

p

63±9

62±8

0.099

45(30)

42(23)

0.371

1114(1966)

753(1449)

0.048*

lnLF (ms2)

6.03±1.07

5.93±0.84

0.270

lnHF (ms2)

5.87±1.39

5.60±1.00

0.032*

lnTP (ms2)

7.48±0.90

7.37±7.39

0.183

LF/HF

1.15(1.77)

1.51(1.86)

0.169

SD1 (ms)

23.7(20.3)

19.4(17.7)

0.049*

α1

1.01±0.33

1.06±0.26

0.112

HR (bpm)
SDNN (ms)
RMSSD (ms)

α1, short-term scaling exponent; HF, high frequency power; HR, heart rate; LF low
frequency power; RMSSD, root mean square of successive differences; SD1, width of the
Poincaré plot; SDNN, standard deviation of normal-to-normal intervals; TP, total power.
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Table 5.3: Multiple linear regression examining contribution of change in metabolic
syndrome risk factors to change in heart rate variability parameters.
Estimate

95% CI

p

F-statistic
5.786

Adjusted R2
0.224

HR
WC
0.129
(0.011, 0.247)
0.033*
SDNN
6.075
0.2314
FPG
-3.332
(-6.629, -0.035)
0.048*
α1
16.58
0.541
SBP
-0.003
(-0.006, -7.0x10-5) 0.045*
TG
-0.038
(-0.078, 2.5x10-3) 0.066
α1, short-term scaling exponent; FPG, fasting plasma glucose; HR, heart rate; SBP,
systolic blood pressure; SDNN, standard deviation of normal to normal intervals; TG,
triglycerides; WC, waist circumference.
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associations with changes in HRV and MetS risk factors overtime were different than
cross-sectional associations. Changes in the HRV parameters that are traditionally
considered to be reflective of vagal activity during supine rest (RMSSD, HF, SD1) were
not independently predicted by change in MetS risk factors, though in cross-sectional
analyses, these HRV parameters were independently predicted by WC and FPG (chapter
3). On the other hand, parameters with sympathetic influence, reflecting overall
variability, or fractal complexity were associated with changes in MetS risk factors. The
change in HR was independently predicted by changes in WC. In the Diabetes
Prevention Program, a higher baseline HR was related to incident diabetes [10].
Preliminary results have suggested that HR may be reflective of sympathetic activity in
MetS population [43]. Abdominal obesity is often considered a cornerstone of MetS, and
in fact is a mandatory risk factor in some MetS definitions [32]. Visceral fat is
hypothesized to be one of the major contributors to insulin resistance [44], which is
associated with sympathetic hyperactivity [45-47]. Together, these findings suggest that
improvements in abdominal obesity may be responsible for normalization of sympathetic
activity seen as a reduction in HR.
Importantly the change in SDNN was independently predicted by the change in FPG. A
longitudinal study showed that in T2D, those within the lowest quartile of two-minute
SDNN had approximately double the risk of incident coronary heart disease and incident
myocardial infarction compared to those in the higher three quartiles [11]. These
findings suggest that improvements in FPG would increase SDNN and therefore,
potentially reduce the risk of cardiovascular complications of T2D. However, the
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increased risk with reduced SDNN was not apparent in participants without T2D [11] and
reduced SDNN did not predict the development of T2D in a general population [9].
In this study, changes in α1 were independently predicted by changes in SBP, with each
mmHg decrease in SBP predicting a small, but significant increase in α1. The breakdown
of fractal complexity (seen as alterations of α1) are associated with either lack of
variability or with complete randomness [41,49], both of which are seen in patients with
advanced disease such as congestive heart failure, complex arrhythmias or postmyocardial infarction patients [50]. Reductions in SBP are known to lower
cardiovascular risk and these findings suggest, that mechanistically, it may be related to
fractal behaviour of heart rate dynamics.
Previous studies have shown that exercise improves HRV [21-24]. This is contrary to
our results which showed that RMSSD, lnHF and SD1 – parameters considered primarily
reflective of vagal activity under resting conditions – were reduced over the 24-week
intervention period rather than increased as expected. However, in some studies, resting
HRV was not a sensitive enough measure to detect subtle changes in autonomic function.
Improvements in autonomic function were detected when HRV was measured during
recovery from moderate intensity exercise [51] or when reflex autonomic control was
assessed by baroreflex sensitivity [52]. Additionally, one study examined the dose
response of exercise for changes in HRV. Completing approximately 50% of national
recommendations for exercise resulted in improvements in lnLF, lnVLF and lnTP, while
meeting national recommendations or exceeding them by 50% improved all time and
frequency domain HRV parameters examined except for HR and LF/HF [53]. Although
the participants in the current study were prescribed exercise according to national

123
physical activity guidelines, it cannot be concluded that targets were met since exercise
was unsupervised. Therefore, changes may not have been seen in this study if
recommendations were not followed appropriately.
Exercise also has benefits for MetS population and is the recommended first-line
treatment for cardiometabolic risk factors [4]. A recent meta-analysis of exercise effects
on cardiovascular risk factors in T2D showed that aerobic exercise resulted in reduced
glycated hemoglobin (a measure of glycemic control over the past 12 weeks), SBP and
TG, with no changes in HDL or WC [54]. This paper did not examine changes in either
FPG or DBP. Our intervention may have failed to change FPG as the mean was within
healthy limits and only seven individuals (6%) had a FPG > 6.1mmol/L to qualify as a
risk factor. Similarly, the mean TG was also within a healthy range. On the other hand,
SBP and DBP were elevated outside normal ranges (>135/85) at V0 and therefore had
greatest potential for improvement.
This intervention used the STEP™ tool for exercise counseling, which has proved to
effectively increase fitness and improve MetS risk factors [35]. Indeed, the 7% and 6%
reductions in SBP and DBP, respectively, are similar to changes that have been seen with
other interventions using STEP™ [35] and are in line with changes in BP with exercise in
hypertensive populations [55]. The 7% increase in VO2max was lower than other studies
employing the STEP™ intervention [35], which suggests that exercise goals may not
have been met and may explain in part lack of change of some MetS risk factors.
Contrary to our hypothesis, there were no differences between EX+T and EX-C. A sixmonth lifestyle intervention including health monitoring, counseling, education, exercise
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and diet improved WC to a greater extent in the intervention compared to the control
group, with no differences in other MetS risk factors [56]. The addition of diet to the
intervention is likely responsible for the improvements in WC. Another study examined
an eHealth-based intervention which included monitoring of BP, steps and body fat; a
four-week education module; telephone counseling; and text and email messages for six
months [57]. After six months, all MetS risk factors had improved except for HDL;
however, this was a pilot study, so a control group was not included [57].
Two systematic reviews have had conflicting results regarding the effectiveness of
eHealth on physical activity and weight loss [27,58]. A review of eHealth interventions
showed that only three of thirteen studies showed improvements in physical activity [27],
while a review of SMS studies showed that three of three studies successfully increased
physical activity and eleven of fourteen studies resulted in weight loss [58]. mHealth
may be more effective than other types of eHealth interventions due to their portability
and convenience and their ability to trigger behaviours or provide support at the
appropriate time. Since the participants in our intervention primarily used their
smartphone as a data portal for submitting measures, the full potential of the smartphonebased intervention may not have been realized. Telemonitoring of blood pressure [59]
and self-management of blood glucose via mobile phone [60] is more effective than usual
care. This mHealth intervention may not have had as much success as it was essentially a
self-management protocol with little interaction between the research team and
participants. Other mHealth interventions have used text messaging for feedback and
encouragement throughout the study. While participants attended an intensive training
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session, more regular contact (either automated or personalized) may have increased the
success of the intervention.
This study was limited to a small, rural population presenting with MetS risk factors;
therefore, results may not be generalizable to urban or other populations. Since the
exercise was unsupervised and pedometer steps were self-reported, the actual amount of
exercise completed cannot be confirmed. Additionally, since dietary changes were not
tracked, some participants may have chosen to change their diet, which may have
contributed to positive changes in MetS risk factors and HRV, and these would not be
accounted for in the analysis. Although there is some evidence that HR may be
indicative of sympathetic activity in MetS [43], direct measures such as measurement of
muscle sympathetic nerve activity would have been ideal. However, these measures are
expensive, time consuming and impractical for large populations.
In conclusion, this six-month intervention showed that changes in HR, SDNN and α1
were associated with changes in MetS risk factors, but HRV parameters more specifically
indicating vagal activity were not. These associations were seen despite the fact that
HRV was not improved by the intervention and the only MetS risk factors that were
improved were WC, SBP and DBP.
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CHAPTER 6
Thesis Summary, Discussion and Conclusions
6.1 Summary of the Thesis
6.1.1 Associations between heart rate variability and metabolic syndrome risk
factors
The purpose of this thesis was to examine relationships between heart rate variability
(HRV) and metabolic syndrome (MetS) risk factors. Chapter 1 was a review of the
literature, which discussed cardiometabolic risk and proposed that based on prognostic
value and relationships with MetS risk factors, HRV may have potential as a novel
cardiometabolic risk factor. Studies examining associations between HRV and MetS
were identified and synthesis of results was recommended.
Chapter 2 was a systematic review with the purpose of describing studies to date
examining the associations between MetS and HRV. This paper showed that HRV was
reduced in women with MetS, though findings were inconsistent in men. This paper also
noted that most HRV indices were not reduced until three or more MetS components
were present – only 24-hour short-term scaling exponent (α1) and five-minute standard
deviation of normal-to-normal intervals (SDNN) were altered with less than three
components. Associations between individual MetS risk factors and HRV parameters
were also reviewed in this paper. It was concluded that associations between MetS risk
factors and HRV parameters varied depending on the population and that greater
consistency in methodology was needed. Additionally, it was suggested that associations
with insulin resistance should be further investigated.
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Chapter 3 was a cross-sectional examination of the associations between HRV, MetS risk
factors and insulin resistance. HRV was not lower in MetS compared to those without
MetS in men. In women, however, HRV was generally lower in MetS, but there were no
differences in HRV parameters reflective of vagal activity. HRV parameters reflective of
parasympathetic activity were independently predicted by waist circumference (WC) and
fasting plasma glucose (FPG), while those reflecting overall variation were predicted by
triglycerides (TG) and high density lipoprotein cholesterol (HDL). Insulin resistance was
only associated with heart rate (HR)
Chapter 5 was a 24-week intervention study, which showed that the changes in MetS risk
factors were generally not associated with changes in HRV parameters. The change in
WC was associated with the change in HR; the change in SDNN was associated with the
change in FPG; and the change in α1 was associated with the change in systolic blood
pressure (SBP).
6.1.2 Exercise intervention as a cardiometabolic risk modifier
Chapter 1 also reviewed the role of exercise as a cardiometabolic risk modifier.
Generally, exercise and physical activity have proved to reduce WC and blood pressure
(BP) and increase HDL in MetS [1]. Studies examining the effects of exercise on HRV
are equivocal with some interventions improving HRV [2-5], while others had no effects
[6]. Exercise prescription may be an important factor. Evidence suggests that frequency
of training may be important to effectively modify HRV, while intensity and duration
may be less important.
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Novel interventions for improving exercise uptake were also examined. The Step Test
and Exercise Prescription (STEP) test has effectively modified both traditional and novel
cardiometabolic risk factors [7] and was the only exercise counseling intervention in
primary care that improved fitness [8]. Mobile health (mHealth) interventions were also
reviewed, which showed promise as a tool for self-management for weight loss, physical
activity and diabetes management. It was suggested that a unique intervention combining
exercise prescription and self-management with mHealth technology had potential as an
intervention to reduce cardiometabolic risk.
Chapter 4 was a pilot study to determine the feasibility and utility of an intervention
utilizing the STEP intervention supported by self-management with a mHealth
application. Twenty-four participants with at least two MetS risk factors volunteered for
this study, which proved that the intervention was feasible and acceptable in a rural
population. Despite the short intervention length (eight weeks), WC, DBP and total
cholesterol were reduced and fitness and physical activity were increased [9,10]. The
high (HF) and low frequency (LF) powers of HRV in normalized units were altered
following the intervention and DBP was correlated with LF/HF, but there were no other
changes in HRV or correlations between HRV and MetS risk factors. Despite these
promising changes, it remained unclear whether the mHealth intervention was of any
added benefit compared to the exercise prescription alone.
Chapter 5 was a randomized controlled trial comparing the effects of a 24 week mHealth
supported exercise intervention to standard of care exercise advice with STEP.
Participants with two or more MetS risk factors were randomly allocated to either an
intervention (n=75) or active control (n=74) group. The intervention group received the
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mHealth supported exercise intervention described in chapter 4, while the control group
received only the exercise testing and prescription. Over the 24-week intervention period,
there were no differences in changes between the intervention and control groups. WC,
SBP and DBP were reduced with no changes in other MetS risk factors. Root mean
square of successive differences (RMSSD), lnHF and Poincaré plot width (SD1) were
reduced over the intervention period with no changes in other HRV parameters.
6.2 Discussion and Future Directions
Recent reviews discussed cardiac autonomic function in the progression of type 2
diabetes mellitus (T2D) [11,12]. The reviews hypothesized that vagal modulation is
reduced initially at the onset of disease and is in fact the first sign of autonomic
dysfunction. The results of this thesis showed that in a population with or without MetS,
there were no differences in vagal indices RMSSD, lnHF or SD1. This suggests that
either vagal indices are reduced before even development of one risk factor and therefore,
no differences are apparent between groups, or that vagal changes occur later in the
progression of disease. Unfortunately, since this thesis did not include a population of
healthy individuals with zero MetS risk factors, this cannot be determined. Over a 24week intervention that improved BP, vagal HRV indices RMSSD, lnHF and SD1 were
reduced. There were no mean changes in MetS status, so the reduction in vagal HRV
indices over time may have been indicative of disease progression despite improvements
in some MetS components (Chapter 5). Additionally, WC and FPG were primarily
associated with all three vagal indices (Chapter 3), suggesting that these two MetS
components may be important in the treatment of cardiometabolic risk. The Diabetes
Prevention Program Outcomes Study showed that the risk of developing T2D was 56%
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lower for participants in whom FPG was reduced to normoglycemia compared to those
with persistently elevated FPG [13]. Reduced SDNN has been shown to be a predictor of
mortality and changes in SDNN were related to changes in FPG (Chapter 5), though in a
cross-sectional examination SDNN was predicted by lipid profiles (Chapter 3). Future
studies should examine the importance of cross-sectional versus longitudinal change
associations between HRV parameters and MetS risk factors.
Although parasympathetic dysfunction has been implicated as the first sign of disease,
the results of this thesis suggest that alterations in HRV associated with overall variation,
complexity and perhaps sympathetic activity may be a better indicator of MetS. Vagal
indices may already be reduced with the presence of one risk factor, making it a poor
indicator of disease progression. However, in cross-sectional studies, only SDNN and α1
were reduced when less than three MetS risk factors were present (Chapter 2). Evidence
suggests that increased sympathetic activity may be present in MetS and that it may, in
fact be mechanistically linked directly to insulin resistance and the progression of disease
[14-16]. The studies included in this thesis were not designed to measure sympathetic
activity directly. Other studies have shown that norepinephrine spillover and muscle
sympathetic nerve activity are increased in MetS [15,16]. The current study showed that
heart rate was increased in MetS compared to those without and preliminary findings
have suggested that heart rate may be a surrogate measure of sympathetic activity in
MetS [14].
Exercise interventions have shown promise in improving MetS and HRV. The DaTA
study (chapter 4) showed some improvements in MetS risk factors and 24h HRV
parameters over eight weeks, but over a 24-week intervention period (chapter 5) some
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MetS risk factors were improved, but 5min resting HRV parameters reflective of vagal
activity were actually lower instead of higher as expected. VO2max was increased 18% in
chapter 4, but only 7% in chapter 5. These differences in fitness improvements may be
responsible for inconsistent findings. Aerobic fitness is protective against mortality [17]
and improvements in autonomic function accompanying increased fitness may play a
role.
Exercise is known to have positive health benefits beyond those directly associated with
HRV. Intensive lifestyle intervention programs reduced the risk of developing T2D in
prediabetes and changes were maintained over a long-term follow-up, though there was a
strong relationship between reduced disease progression and continuance of lifestyle
intervention behaviours [18]. These finding highlight the importance of post-program
support for long-term maintenance. Knowledge translation activities are important to
translate research protocols into useable programs.
mHealth applications have the potential to reach a broad population and provide a
convenient and effective medium for delivery of interventions. Although there is a
growing body of literature in this field, studies to date are heterogeneous with respect to
study population, intervention delivery and reported outcomes. With rapid technological
developments it is difficult to plan and implement robust clinical mobile health trials
within the current research environment before technology is outdated. Many published
mHealth interventions do not use the technology to its full potential and better results
may be realized by utilizing as many smartphone features as possible in an intervention.
Future research should examine published literature to determine the most beneficial use
of mobile technology for optimal health results. Smartphone applications are being
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developed at a fast rate, with many aimed at health and behaviour management.
However, a review cautioned that few applications are based in theory [19] and that the
success of mobile health interventions could be maximized by developing evidence-based
applications specific to population needs. This will be important if mHealth becomes
integrated into clinical practice in the future.
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APPENDIX 1:
The STEP™ Protocol
The STEP™ Protocol includes two basic components: the stepping fitness test and an
exercise prescription.
Part A: The stepping fitness test
Begin the stepping fitness test by demonstrating the stepping pattern to patients: stepping
one foot at a time up both steps and back down again (“up, up, together, down, down,
together”). Emphasize that only one foot is on the middle step at any one time. Also
remind the patient that one step is counted after stepping up to the top step and returning
back down to the starting position. Instruct the patient to complete 20 consecutive
stepping cycles at a self-selected normal pace (similar to the pace they would use to
climb stairs). When the patient is ready to begin, start the timer as their first foot leaves
the ground. During the test, count each step aloud as they complete it. Offer
encouragement and watch for signs of fatigue or balance problems (or any signs of
concern for their safety). Although the individual self-selects the pace to complete the
stepping test, encourage them to maintain a consistent speed. For example, if they are
“racing” through it, be sure to encourage the patient to slow down to ensure valid results.
As the patient performs the last step, be prepared to take their heart rate when they
complete the test. Take the post-exercise heart rate, palpating radially in a 6 second
count. The patient can rest while you complete the equation for predicted aerobic
capacity.
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Part B: Exercise prescription
Calculate the patient’s target training heart rate, using 70-85% of their age-predicted
maximal heart rate as a target. Generally, individuals with lower aerobic fitness levels
should be advised to stay at the lower end of their target HR zone (70%). Those with high
fitness levels should be encouraged to aim for the higher range (80-85%) depending on
their current physical activity/exercise regimes and their limitations.
Complete the exercise prescription note for the patient, including: date of test, predicted
VO2max, target training heart rate (including beats per minute and beats in 10 seconds),
and frequency of activity. (Appendix Figure 1) It is helpful to provide patients with a
copy of Canadian physical activity guidelines during this process, which highlight that
Canadian adults should aim for at least 150 minutes of moderate- to vigorous-intensity
physical activity each week and that this can be accumulated in a minimum of 10-minute
bouts (CSEP, 2011). During the exercise prescription process, it can be helpful to
describe the term VO2max as well as training heart rate to patients. The definitions below
have been applied for this purpose.


VO2max is a measure of your cardiorespiratory (or aerobic) fitness. It is a score
of how well your heart, lungs, and muscles work together. The higher this number
is, the more fit you are. You can become more fit by increasing your aerobic
physical activity. Some examples of aerobic physical activity include walking,
swimming, or shovelling the driveway.



Training Heart Rate – In order to improve your fitness, it is important to check
your heart rate during physical activity. This training heart rate has been
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prescribed specifically for you based on your exercise results. The easiest way to
check your pulse is to count how many times you feel your heart beat in 10
seconds.
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Appendix Figure 1: STEP Worksheet

STEP™ Test
Calculation Worksheet
Participant Data:
Sex (male=1, female=2)
Age (years)
Weight (kg)
Time required for STEP test (sec)
Heart Rate after STEP test (bpm)

Calculations:
Step

Calculation

Answer

1

(1511/time)*weight/heart rate

=

2

([Ans Step1] *0.124) – (age*0.032) – (sex*0.633) + 3.9

=

3

([Ans Step 2] *1000)/weight

=
 VO2max
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Appendix Figure 2: STEP Exercise Prescription

EXERCISE PRESCRIPTION

Date: ____________________

VO2max: ____________________ ml/kg/min

Classification:
Needs Improvement

Training Heart Rate:

Fair

Good

Excellent

____________________ beats/min
____________________ beats in 10 sec

Type of activity: ________________________________________
You should try to be active on most days of the week, and include activities
that strengthen muscles and bones on 2 days of the the week.

Time: Complete a minimum of 10 minutes per session, to reach a total of at
least 150 minutes per week to achieve health benefits.

Interrupt time sitting still every 20 minutes
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